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Abstract
Fatty acid metabolism governs critical cellular processes in multiple cell types. The goal of my
dissertation was to investigate the intersection between fatty acid metabolism and hematopoiesis.
Although fatty acid metabolism has been extensively studied in mature hematopoietic subsets during
inflammation, in developing hematopoietic cells the role of fatty acid metabolism, in particular by 12/
15-Lipoxygenase (12/15-LOX), was unknown. The observation that 12/15-LOX-deficient (Alox15) mice
developed a myeloid leukemia instigated my studies since leukemias are often a consequence of
dysregulated hematopoiesis. This observation lead to the central hypothesis of this dissertation which is
that polyunsaturated fatty acid metabolism mediated by 12/15-LOX participates in hematopoietic
development. Using genetic mouse models and in vitro and in vivo cell development assays, I found that
12/15-LOX indeed regulates multiple stages of hematopoiesis including the function of hematopoietic
stem cells (HSC) and the differentiation of B cells, T cells, basophils, granulocytes and monocytes. Within
hematopoietic development, I concentrated on the mechanisms that underlie the defects in HSC function
and monocyte development since these defects likely contribute to the myeloid leukemogenesis in
Alox15 mice. Interestingly, I determined that 12/15-LOX promotes HSC self-renewal and quiescence,
which is associated with the activation of canonical Wnt signaling. Moreover, my studies demonstrate
that 12/15-LOX-mediated redox signaling of SHP-2 and the transcription factor ICSBP/IRF-8 promotes
monocyte development while inhibiting granulocyte development. This pathway is also conserved in
IL-12p40 expression in macrophages. Therefore, I establish 12/15- LOX as a critical regulator of
hematopoiesis and provide insight into novel mechanisms whereby HSC function and monocyte cell fate
decisions are regulated. These findings have implications for leukemogenesis and immunity.
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ABSTRACT
FATTY ACID METABOLISM MEDIATED BY 12/15-LIPOXYGENASE IS A
NOVEL REGULATOR OF HEMATOPOIETIC STEM CELL FUNCTION AND
MYELOPOIESIS
Michelle Kinder
Advisor: Ellen Puré
Fatty acid metabolism governs critical cellular processes in multiple cell types.
The goal of my dissertation was to investigate the intersection between fatty acid
metabolism and hematopoiesis. Although fatty acid metabolism has been
extensively studied in mature hematopoietic subsets during inflammation, in
developing hematopoietic cells the role of fatty acid metabolism, in particular by
12/15-Lipoxygenase (12/15-LOX), was unknown. The observation that 12/15LOX-deficient (Alox15) mice developed a myeloid leukemia instigated my studies
since leukemias are often a consequence of dysregulated hematopoiesis. This
observation lead to the central hypothesis of this dissertation which is that
polyunsaturated fatty acid metabolism mediated by 12/15-LOX participates in
hematopoietic development. Using genetic mouse models and in vitro and in
vivo cell development assays, I found that 12/15-LOX indeed regulates multiple
stages of hematopoiesis including the function of hematopoietic stem cells (HSC)
and the differentiation of B cells, T cells, basophils, granulocytes and monocytes.
Within hematopoietic development, I concentrated on the mechanisms that
underlie the defects in HSC function and monocyte development since these
xvi

defects likely contribute to the myeloid leukemogenesis in Alox15 mice.
Interestingly, I determined that 12/15-LOX promotes HSC self-renewal and
quiescence, which is associated with the activation of canonical Wnt signaling.
Moreover, my studies demonstrate that 12/15-LOX-mediated redox signaling of
SHP-2 and the transcription factor ICSBP/IRF-8 promotes monocyte
development while inhibiting granulocyte development. This pathway is also
conserved in IL-12p40 expression in macrophages. Therefore, I establish 12/15LOX as a critical regulator of hematopoiesis and provide insight into novel
mechanisms whereby HSC function and monocyte cell fate decisions are
regulated. These findings have implications for leukemogenesis and immunity.

xvii

INTRODUCTION
Hematopoiesis is the dynamic process whereby all blood cells develop
from a common progenitor, the hematopoietic stem cell (HSC). Under
homeostatic conditions, hematopoiesis must continuously replenish billions of
cells of the blood system daily including erythrocytes and neutrophils, which
exhibit short half-lives. As HSC are relatively rare, but there is an abundance of
blood cells, the process of hematopoiesis must be tightly regulated to produce
appropriate numbers of each blood cell type. Moreover, the process of
hematopoiesis must adapt to stresses such as infection. Dysregulation of
hematopoiesis can result in immunodeficiencies, anemias or leukemias.
Therefore, it is important to study the molecular processes that underlie normal
and malignant hematopoietic development. In this dissertation, I define
polyunsaturated fatty acid metabolism mediated by 12/15-Lipoxygenase (12/15LOX) as a critical regulator of hematopoiesis. Specifically, I elucidate the
mechanisms whereby 12/15-LOX regulates HSC function and myelopoiesis.
Hematopoietic Stem Cells
HSCs are multipotent cells that give rise to all of the cells of the blood
during hematopoiesis (Figure 1). HSCs possess the unique ability to undergo
asymmetric division by proliferating in a fashion that preserves self-renewal and
also allows for differentiation to give rise to mature blood cells. Because markers
for HSCs have been identified (Wilson et al., 2007) and assays for measuring
HSC function are well defined (Purton and Scadden, 2007),
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HSCs are an attractive model system for understanding tissue stem cells in
general. The study of HSCs provides insight into the regulation of stem cells
during infection, aging, and oncogenesis.
HSCs have been identified using various phenotypic markers. Although
murine HSCs are enriched within the Lin-Sca1+cKit+ (LSK) cell compartment,
they can be further subdivided both functionally and phenotypically into multiple
subtypes by a combination of other markers including CD34 (Morel et al., 1996),
Flt3 (Yang et al., 2005) and the signaling lymphocyte activation molecule (SLAM)
markers CD48 and CD150 (Kiel et al., 2005). Long-term HSCs (LT-HSC) are the
most primitive HSC and fully reconstitute the hematopoietic compartment of
lethally irradiated animals. LT-HSCs are highly enriched (1 of every 2 cells) within
the subset of cells that are identified based on phenotypic profile LSKFlt3-CD48CD150+CD34- (Wilson et al., 2007). They reside in a hypoxic niche and are
generally quiescent (Cheshier et al., 1999; Wilson et al., 2007) Recent studies
have subdivided the LT-HSC compartment into dormant and activated LT-HSC
based on cell retention assays using bromodeoxyuridine (BrdU) and histone-2BGFP labeling. Dormant LT-HSCs rarely divide but can become activated to
undergo asymmetric division in order to respond to environmental stresses such
as chemotherapy treatment (for example, 5-fluorouracil, 5-FU), cytokine
stimulation and hematopoietic reconstitution. When stimulation wanes and
homeostasis is reestablished, activated LT-HSCs become dormant again (Wilson
et al., 2008). In comparison, short-term HSCs (ST-HSC) have decreased ability
for long term reconstitution of lethally irradiated animals and are more
3

proliferative than LT-HSCs (Figure 1). ST-HSCs can further differentiate to
become multipotent progenitors (MPP), which retain the ability to generate all
blood lineages, but lose the potential to self-renew. Subpopulations of MPP may
differ in their ability to differentiate into various blood cell types (Wilson et al.,
2007).
One way of measuring HSC function is by measuring their ability to
reconstitute lethally irradiated hosts. There are multiple factors that contribute to
HSC function in this regard (Figure 2). The numbers, homing and survival of
HSCs can effect their ability to function. Defective asymmetric division also
effects HSC function. Inability to self-renew or differentiate compromises HSC
function. The ability of HSCs to self-renew and differentiate is regulated through
their environmental niche, cytokine signaling and the orchestrated activities of
various transcription factors including growth factor independent-1 (Gfi-1), Bmi,
homeobox B4 (Hox4b) and Pu.1 (Blank et al., 2008). However, less is known
about the signaling pathways that regulate HSC function. In this dissertation, I
demonstrate that signaling downstream of 12/15-LOX-mediated fatty acid
metabolism regulates HSC self-renewal.
The unique capacity of HSCs to both differentiate and self-renew is closely
related to their proliferative capacity (Ficara et al., 2008; Nemeth et al., 2006).
Highly proliferative HSCs are less efficient at reconstituting lethally irradiated
mice (Passegue et al., 2005). Thus, HSCs that lack cell cycle inhibitors required
to maintain quiescence, such as p21cip/WAF, are functionally defective
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(Cheng et al., 2000). This dissertation will demonstrate that HSCs from 12/15LOX-deficient mice, Alox15, exhibit defective quiescence and HSC function.
Canonical Wnt Signaling
As mentioned, little was known about signaling pathways that regulate
HSC function. Canonical Wnt signaling is one such pathway that has been
implicated to regulate HSC function although its importance remains debated.
Canonical Wnt signaling is believed to regulate HSC self-renewal and is known
to play a role in other cell types, such as promoting B and T lymphocyte
development (Staal and Sen, 2008) and enhancing self-renewal of tumor cells
(Fodde and Brabletz, 2007). There are 19 defined Wnt ligands that are lipid
modified by palmitoylation, which is required for its secretion from the cell
(Takada et al., 2006; Willert et al., 2003). Wnt ligands act on 10 different Frizzled
receptors and two low-density lipoprotein receptor-related protein (LRP) coreceptors.
Wnt signaling is based on the availability of the ligands, receptors and
secondary messengers. Up to 10 signaling pathways have been implicated
downstream of Wnt signaling. The canonical signaling pathway results in
stabilization and nuclear translocation of the transcription factor β–catenin
(Malhotra and Kincade, 2009). During canonical signaling, ligands such as
Wnt3a or Wnt 10b activate the frizzled receptor and LRP co-receptor to activate
disheveled. Disheveled functions by inhibiting the β–catenin destruction complex
which is composed of axin, glycogen synthase kinase 3 (GSK-3β) and
adenomatous polyposis coli (APC). In the absence of canonical Wnt
6

signaling, this complex binds and phosphorylates β–catenin targeting it for
ubiquitination and subsequent proteolysis. When members of this complex such
as axin are over-expressed, β–catenin protein is degraded and signaling is
reduced, resulting in decreased HSC function and self-renewal (Reya et al.,
2003). However, in the presence of canonical Wnt signaling β–catenin and a
related protein, γ–catenin, are stabilized and can translocate to the nucleus
where it acts as a co-activator for the lymphoid enhancer factor (LEF) and T cell
factor (TCF) transcription factors (Malhotra and Kincade, 2009). The noncanonical Wnt signaling pathway is activated in part by the Wnt5a ligand and can
inhibit canonical Wnt signaling (Nemeth et al., 2007).
The role of canonical Wnt signaling in HSC function has been
controversial because inducible deletion of β–catenin and inducible co-deletion of
β–catenin/γ–catenin using Mx-Cre had little effect on HSC function (Cobas et al.,
2004; Jeannet et al., 2008; Koch et al., 2008). However, in these studies, the
LEF/TCF reporter was still active (Jeannet et al., 2008). On the other hand,
recent evidence points to a critical role for canonical Wnt signaling in regulation
of HSC quiescence and self-renewal. For instance, deletion of β–catenin using
Vav-cre, resulted in defective self-renewal of LT-HSCs (Zhao et al., 2007). HSC
function was also compromised due to defective self-renewal when the canonical
ligand Wnt3a was deleted (Luis et al., 2009). Over-expression of Dickkopf-1, an
inhibitor of canonical Wnt signaling, increased HSC proliferation and decreased
HSC self-renewal (Fleming et al., 2008). Conversely, when Wnt signaling was
elevated, such as in Hmgb3-deficient HSCs, the ability of HSCs to self-renew
7

and repopulate following hematopoietic stress were enhanced (Nemeth et al.,
2006). Taken together, these data support a role of canonical Wnt signaling in
HSC self-renewal. This dissertation defines 12/15-LOX as a novel regulator of
canonical Wnt signaling.
Myelopoiesis
Myelopoiesis is the process whereby myeloid cells, monocytes and
granulocytes, are generated. Although originally thought of as a linear pathway,
recent studies have shown that immature intermediates once thought to give rise
exclusively to cells of the lymphoid lineage also possess myeloid cell potential
(Bell and Bhandoola, 2008). These studies have caused the field to rethink the
hierarchical model of myeloid cell differentiation (Ceredig et al., 2009). However,
in order to concentrate on myeloid lineage differentiation rather than cells arising
during lymphoid differentiation, I will refer to the classical model of myeloid cell
differentiation (Figure 3). However, it is important to note that the lineage
decisions between monocytes and granulocytes remain a mutually exclusive cell
fate decision that is conserved throughout various models of hematopoiesis.
HSCs are multipotent and can differentiate into any hematopoietic lineage.
However, as HSC differentiate they lose their ability to self-renew and are more
restricted in their differentiation potential. HSC differentiate into MPP, which lack
the ability to self-renew but can still differentiate into all lineages. MPP initiate T
cell differentiation by seeding the thymus (Schwarz and Bhandoola, 2004),
initiate B cell differentiation by differentiating into common lymphoid progenitors
(CLP) (Kondo et al., 1997) or initiate myeloid cell differentiation by becoming
8
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common myeloid progenitors (CMP) (Akashi et al., 2000). CMPs can support
erythroid cell differentiation by becoming megakaryocyte-erythroid progenitors
(MEP) and subsequently produce megakaryocytes, red blood cells and platelets.
On the other hand, CMPs can differentiate to produce granulocyte-macrophage
progenitors (GMP), which in turn produce either granulocytes or macrophages
and types of dendritic cells (Akashi et al., 2000).
The process of myelopoiesis is regulated by cytokines and by transcription
factors (Figure 3). The cytokine granulocyte-macrophage stimulating factor (GMCSF) promotes the production of GMP, while granulocyte colony stimulating
factor (G-CSF) and macrophage colony stimulating factor (M-CSF) instruct
granulocyte and monocyte lineage fate decisions, respectively. The signaling
pathways of G-CSF and M-CSF have recently been elucidated. M-CSF activates
phospholipase Cγ2 (PLCγ2), which in turn stimulates extracellular signalregulated kinase (Erk) activation. Activated Erk leads to transcriptional activity of
c/EBPα:c-fos and c-jun heterodimers and Egr-1 which drives monocyte
differentiation. On the other hand, G-CSF stimulates signal transducers and
activators of transcription 3 (Stat3) activation leading to phosphorylation and
increased activity of the phosphatase Src homology 2-containing tyrosine
phosphatase-2 (SHP-2) and formation of CCAAT/enhancer binding protein-α
(c/EBPα) homodimers, which mediate transcription of genes that promote
monocyte differentiation (Jack et al., 2009). Though the exact role of SHP-2
during granulopoiesis is not known, it is known to dephosphorylate and
subsequently inhibit the transcriptional activity of interferon regulatory factor10

8 (IRF-8, also known as interferon consensus sequence binding protein, ICSBP),
which is a critical regulator of monocyte differentiation (Huang et al., 2006;
Tamura and Ozato, 2002). Interestingly, SHP-1 and SHP-2 are subject to
oxidative modification that results in inactivation (Chen et al., 2009a; Heneberg
and Draber, 2005; Kwon et al., 2005; Weibrecht et al., 2007). Moreover, reactive
oxygen species (ROS) generated by lipoxygenases have been implicated in
oxidative inactivation of SHP-2 during density dependent inhibition of cell growth
(Pani et al., 2000). In chapter 3, I demonstrate that inhibition of SHP-1/2 restores
monocyte development and interleukin-12p40 (IL-12p40) production in Alox15
cells, suggesting a pathway by which 12/15-LOX-mediated redox signaling
regulates myelopoeisis and inflammation through ICSBP/IRF-8
As described above, cytokines stimulate signaling pathways that result in
the activation of transcription factors. The cell fate decision between monocyte
and granulocytes are mutually exclusive and pathways that promote one cell fate
often inhibit the other. For instance, the transcription factors early growth
response factor-1 (Egr-1), Egr-2, ICSBP/IRF-8, NGFI-A binding protein 2 (Nab2), c-Jun and HoxA10 promote monocyte differentiation and repress granulocyte
differentiation while Gfi-1 promotes granulocyte differentiation and inhibits
monocyte differentiation (Friedman, 2007; Hock et al., 2003). In addition, the
relative levels of transcription factors function as a rheostat to control
differentiation; increased levels of PU.1 promote monocyte differentiation while
higher levels of the transcription factor C/EBPα promote granulocyte
differentiation (Dahl et al., 2003).
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ICSBP/IRF-8
The interferon regulatory factor family of transcription factors is known to
regulate cell fate decisions and immune regulation (Tamura et al., 2008). One
such family member, ICSBP/IRF-8 is an immune cell specific transcription factor
important in development of multiple hematopoietic cell types. ICSBP/IRF-8regulates B cell, dendritic cell and monocyte development and absence of
ICSBP/IRF-8 in ICSBP/IRF-8-deficient mice leads to deficiencies of these
populations (Lu et al., 2003; Tsujimura et al., 2002). Moreover, the disruption of
myeloid cell development in ICSBP/IRF-8-deficient mice results in chronic
myelogenous leukemia (CML)-like myeloproliferative disorder that progresses to
a blast crisis (Holtschke et al., 1996).
The expression of ICSBP/IRF-8 and other members of the interferon
regulatory factor family members are activated by interferon-γ (IFN-γ) signaling
through Stat1 (Kanno et al., 1993). ICSBP/IRF-8 consists of 3 domains: DNA
binding domain, transcription repressor domain and an IRF-association domain
(Sharf et al., 1995). IRF-8 both represses and activates transcription of distinct
subsets of genes. ICSBP/IRF-8 activates transcription of genes including
neurofibromin (NF-1) (Zhu et al., 2004), p15INK4b (Schmidt et al., 2004),
phagocyte oxidase91 (phox91) (Eklund et al., 1998), phox67 (Eklund and Kakar,
1999), B-lymphocyte-induced maturation protein-1 (Blimp-1) (Tamura et al.,
2003) and IL-12p40 (Wang et al., 2000) and represses transcription of other
genes including bcl-xl (Gabriele et al., 1999), bcl-2 (Burchert et al., 2004), and
disabled-2 (Dab2) (Rosenbauer et al., 2002).
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ICSBP/IRF-8-transcriptional activity is regulated post-translationally on
multiple levels. The gene targeting and transcriptional activity of ICSBP/IRF-8 is
conferred in part by its binding to other transcription factors such as PU.1 and
other IRF family members (Eklund et al., 1998). The association of ICSBP/IRF-8
with other transcription factors is also believed to regulate whether it functions as
a transcriptional activator or repressor. Tyrosine phosphorylation of ICSBP/IRF-8
inhibited its direct binding to DNA but allowed for ICSBP/IRF-8 to bind DNA in
association with IRF-1 or IRF-2 (Sharf et al., 1997). On the other hand, the
phosphatases SHP-1 and SHP-2 de-phosphorylated ICSBP/IRF-8 causing
functional inactivation by inhibiting its association with other transcription factors
such as PU.1 (Kautz et al., 2001; Huang et al., 2006). One mechanism whereby
oncogenic constitutively active SHP-2 contributes to myeloid leukemia is by
decreasing levels of the ICSBP/IRF-8-mediated gene target NF-1, which in turn
increases cytokine sensitivity (Huang et al., 2006; Koenigsmann et al., 2009).
Moreover, ICSBP/IRF-8 is subject to regulation by proteosomal degradation
through Cbl ubiquitin ligase after LPS/IFNγ stimulation (Xiong et al., 2005).
Lastly, previous data from our laboratory demonstrated that ICSBP/IRF-8 is also
regulated at the level of nuclear accumulation. 12/15-LOX-deficient myeloid
splenocytes exhibited similar levels of total but decreased nuclear accumulation
of ICSBP/IRF-8. This regulation was mediated in part by PI3-K (Middleton et al.,
2006b). In this dissertation, I elucidate that 12/15-LOX regulates ICSBP/IRF-8
nuclear accumulation through a redox-dependent mechanism.
ICSBP/IRF-8 and its target genes are implicated in HSC function.
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ICSBP/IRF-8 expression is decreased in aging HSC (Stirewalt et al., 2008),
which are known to be functionally compromised (Roobrouck et al., 2008). In
addition, ICSBP/IRF-8 represses Dab2 transcription, and ICSBP/IRF-8-deficient
cells express high levels of Dab2 (Rosenbauer et al., 2002). Others have shown
that Dab2 negatively regulates canonical Wnt signaling by stabilizing axin and
the β-catenin degradation complex while inhibiting disheveled (Hocevar et al.,
2003; Jiang et al., 2008). Our data demonstrate that Dab2 expression is also
increased in Alox15 HSC, which results in decreased canonical Wnt signaling. As
described above, canonical Wnt signaling regulates HSC function and may
contribute to the defects in Alox15 HSC.
ICSBP/IRF-8 critically promotes monocyte differentiation in conjugation
with PU.1 by activating genes that stimulate monocyte differentiation while
inhibiting genes that promote granulocyte differentiation (Tamura et al., 2000).
ICSBP/IRF-8-deficient mice exhibited defective monocyte differentation and
enhanced granulocyte differentiation that was corrected by retrovirally restoring
IRF-8 expression (Tsujimura et al., 2002). Moreover, ICSBP/IRF-8-deficient
mice developed a granulocytic chronic myelogenous leukemia (CML)-like
leukemia that progresses into a blast crisis (Holtschke et al., 1996). In addition to
its tumor suppressor role in murine leukemia, ICSBP/IRF-8 may also function as
a tumor suppressor in human CML. ICSBP/IRF-8 is down-regulated in human
CML (Schmidt et al., 1998; Schmidt et al., 2001) and has been shown to
antagonize BCR-ABL-induced oncogenesis (Hao and Ren, 2000; Tamura et al.,
2003; Burchert et al., 2004). Interestingly, ICSBP/IRF-8 also functions as a
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tumor suppressor in other leukemias (Gurevich et al., 2006; Ma et al., 2006;
Konieczna et al., 2008; Schwieger et al., 2002).
ICSBP/IRF-8 critically mediates immunity by transcribing IL-12p40 mRNA
in antigen presenting cells, dendritic cells and macrophages (Hein et al., 2000)
(Jayakumar et al., 2008; Scharton-Kersten et al., 1997). Loss of IL-12p40 gene
expression in IRF-8/ICSBP-deficient mice results in susceptibility to myriad of
viruses, parasites and bacteria including vaccinia virus, lymphocytic
choriomeningitis virus (Holtschke et al., 1996) Listeria monocytogenes (Fehr et
al., 1997), Yersinia enterocolitica (Hein et al., 2000), Toxoplasma Gondii
(Scharton-Kersten et al., 1997), and Leishmania major (Giese et al., 1997).
Because of the development of a myeloproliferative disease in ICSBP/IRF-8
deficient mice, less is known about the role of ICSBP/IRF-8 during chronic
inflammatory events. Development of a floxed ICSBP/IRF-8 mouse would
facilitate further studies into the role of ICSBP/IRF-8 in immunity and chronic
inflammation.
Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPN) are a result of defective myelopoiesis
and are characterized by a clonal expansion of myeloid subsets. Human MPNs
include CML, chronic neutrophilic leukemia, polycythemia vera, primary
myelofibrosis, essential thrombocythemia, chronic eosinophilic leukemia,
mastocytosis, and unclassifiable MPNs (Thiele, 2009).
Defects in transcription factors that regulate myelopoiesis contribute to
myeloid leukemias in both mice and humans. For instance, ICSBP/IRF-8
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regulates monocyte differentation and inhibits granulocyte differentiation (Tamura
et al., 2000; Tsujimura et al., 2002). In ICSBP/IRF-8-deficient mice, a
granulocytic CML-like myeloproliferative neoplasm results (Holtschke et al.,
1996). Moreover, during human CML, ICSBP/IRF-8 expression is decreased
(Schmidt et al., 1998). Similarly, the transcription factor JunB regulates
myelopoiesis and loss of JunB in the myeloid lineage leads to a CML-like MPN
(Passegue et al., 2001). Human CML is also associated with decreased JunB
expression (Hoshino et al., 2009; Yang et al., 2003). Another example is PU.1,
which regulates early myeloid differentiation. PU.1-deficient mice have an early
block in myeloid differentiation and disruption of PU.1 results in an acute myeloid
leukemia in both mice and humans (Anderson et al., 1998; Mueller et al., 2002).
Alterations in cell signaling can also underlie myeloid leukemogenesis.
Loss of NF-1 gene expression in both mice and humans results in hyperactive
Ras and cytokine signaling leading to juvenile chronic myelogenous leukemia
(Shannon et al., 1994; Kalra et al., 1994; Bollag et al., 1996). Similarly, activating
mutations in SHP-2 also stimulates Ras activation resulting in cytokine
hypersensitivity and myelogenous leukemia (Niihori et al., 2005; Loh et al., 2004;
Schubbert et al., 2005). Polycythemia vera, primary myelofibrosis and essential
thrombocythemia represent related MPNs often caused by activating mutations
in Jak2 (Levine and Gilliland, 2008). On the other hand, human CML is
characterized by presence of a translocation known as the Philadelphia
chromosome involving chromosomes 9 and 22. The Philadelphia chromosome is
a fusion of Bcr to Abl that results in a constitutively active tyrosine kinase.
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Bcr-Abl activates multiple signaling pathways to promote oncogenic signaling
including activation of PI3-K and Ras signaling (Ren, 2005). Treatment of CML
with the tyrosine kinase inhibitor imatinib has resulted in about 80% clinical and
cytogenic remissions; however, treatment is not curative (Vardiman, 2009).
Since HSCs are the only stage at which self-renewal can occur during
normal hematopoiesis often the mutations that lead to leukemia are found in
HSCs. For instance, JunB deficiency must be in the HSCs and not in later stages
of hematopoiesis for leukemia to result (Passegue et al., 2004). Moreover,
deficiency of the tumor suppressor phosphatase tensin homolog (PTEN) in HSCs
results in a myeloid leukemia (Yilmaz et al., 2006). In human leukemia, the BcrAbl translocation is found in HSCs and drives the chronic phase of disease.
However, a secondary mutation develops in GMPs that confers the ability to selfrenew and drives the blast crisis disease phase (Jamieson et al., 2004).
Fatty acid metabolism
Metabolism describes the chemical processes in living organisms that
support cellular and organismal functions. Fatty acid metabolism describes
chemical reactions that involve fatty acids, such as those found in triglycerides
and membrane phospholipids. Triglycerides serve to generate energy for the
body and are stored in adipose tissue. Meanwhile, the fatty acid components of
cell membranes can be directly modified enzymatically or catabolized through the
actions of phospholipases to generate free fatty acids. Fatty acid metabolism
generates secondary messengers that serve as signaling molecules to regulate
cellular processes including vascular homeostasis, platelet aggregation and
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inflammatory responses.
During polyunsaturated fatty acid metabolism, lipid substrates such as
arachidonic acid (AA) or lineolic acid are released from the cell membranes by
phospholipase A2. The major product AA is then metabolized through the action
of oxidative enzymes including cytochrome p450, cyclooxygenases, and
lipoxygenases to produce multiple bioactive lipid mediators including
eicosanoids, prostaglandins, leukotrienes and lipoxins (Figure 4). These products
are generated in a cell-context dependent manner and can signal in both
autocrine and paracrine fashions (Harizi et al., 2008). Reactive oxygen species
(ROS) are generated as a byproduct of the oxidation step of AA and as the lipid
products are further metabolized by gluthathione reductase activity (Kim et al.,
2008) (Figure 4). The myriad lipid mediators often have opposing functions and
hence signaling is dependent on the relative concentration of multiple lipid
mediators (Harizi et al., 2008).
Cytochrome p450 and Cyclooxygenases
The cytochrome p450 superfamily is composed of 57 members and is
expressed in multiple cell types including liver, adrenal glands, and peripheral
blood leukocytes where its expression can be induced by various stimuli (Dy and
Schneider, 2004). Cytochrome p450 metabolizes AA to produce
hydroxyeicosatetraenoic acids (HETE) and epoxyeicosatrienoic acids (EET).
Cytochrome p450 functions in angiogenesis and plays a protective role during
myocardial and cerebral ischemia. Moreover, lipid mediators produced by
cytochrome p450 have been shown to play an anti-inflammatory role in
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endothelium and in the kidney (Spector, 2009). Cytochrome p450 lipid products
exert their effects extracellularly, through a putative EET receptor or by binding
other lipid receptor agonists which are coupled to signaling pathways, and
intracellularly by acting directly on ion channels, cell signaling proteins,
transcription factors or by incorporation into membrane phospholipids.
Interestingly, cytochrome p450 lipid products can have opposing functions. For
example, 20-HETE acts on smooth muscle cells as a vasoconstrictor while EET
acts as a vasodilator (Kroetz and Zeldin, 2002).
Cyclooxygenases catabolize AA to produce prostaglandins, which exert
their pleiotropic effects by binding to multiple G-protein coupled receptors that
vary in their secondary signaling pathways and cellular expression (Harizi et al.,
2008). Cyclooxygenase-1 (COX-1) is constitutively expressed in most cell types
and is highly expressed in endothelium, monocytes, platelets, renal collecting
tubules and seminal vesicles. The expression of cyclooxygenase-2 (COX-2) is
inducible and restricted to cells involved in reproduction, immunity, renal
physiology, neutrotransmission, bone resorption and pancreatic secretion. COX2 is induced by multiple proliferative and inflammatory stimuli including tumor
necrosis factor-α, lipopolysaccharide (LPS) and IL-1 and decreased by
glucocortioids and anti-inflammatory stimuli (Smith et al., 2000). Nonsteroidal
anti-inflammatory drugs, such as aspirin and ibuprofen, target the COX isoforms
as a treatment for pain, fever, and inflammation (Rouzer and Marnett, 2009).
COX-2 is pro-inflammatory in peripheral tissues and participates in inflammatory
diseases such as cancer and in rheumatoid arthritis (Obukowicz and
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Ornberg, 1999; Rouzer and Marnett, 2009; Tuynman et al., 2008). COX-2
specific inhibitors have been developed to treat chronic inflammation but its use
is limited due to cardiovascular toxicity, which is associated with decreased PGI2
production in the blood vessel wall (Rho et al., 2009; Rouzer and Marnett, 2009).
On the other hand, COX-2 can also decrease inflammation in a cell-context
dependent manner. For instance, COX-2 through prostaglandin E2 (PGE2) can
decrease inflammation in secondary lymphoid organs by decreasing IL-12p40
production through an IL-10 dependent mechanism in dendritic cells (DC),
inducing forkhead box P3+ (FoxP3) regulatory T cells, suppressing natural killer
(NK) cell IFNγ production and inducing B cell immunoglobulin (Ig)-class switching
(Harizi et al., 2008; Harizi and Gualde, 2006).
Lipoxygenases
Lipoxygenases are a diverse class of oxidative enzymes that catalyze
oxygenation of AA and lineolic acid to generate numerous hydroperoxyeicosatetraeoic acid (HpETE) intermediates (Conrad, 1999). 5-Lipoxygenase (5LOX) is an enzyme primarily expressed in leukocytes that catalyzes the
conversion of AA to 5-HpETE and subsequently catalyzes the reaction of 5HpETE to generate leukotriene A4. 5-LOX is bound by 5-lipoxygenase activating
protein that enhances its substrate binding. Leukotriene A4 is subsequently
converted to leukotriene C4 (LTC4) in cells that express LTC4 synthase such as
mast cells, eosinophils, and endothelial cells or converted to leukotriene B4 in
cells that express LTA4 hydrolase such as neutrophils and monocytes. LTC4 can
be further metabolized to produce LTD4, and LTE4. Leukotrienes are
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released from the cell by protein transporters and signal by binding G-coupled
protein receptors BLT1, BLT2, cysLT1, cysLT2 (Peters-Golden and Henderson,
2007). The leukotrienes produced depend on cellular context, and their signaling
depends on the expression of receptors on neighboring cells. Leukotrienes
stimulate leukocyte recruitment of multiple cell types to inflammatory sites and
their subsequent activation (Islam et al., 2006; Tager et al., 2000; Lee et al.,
1999; Shin et al., 2006; Taube et al., 2006). Leukotrienes also increase Th2
inflammatory responses, vascular permeability, and bronchoconstriction and
contribute to the pathogenesis of asthma, cardiovascular disease, arthritis and
cancer (Hyde and Missailidis, 2009; Peters-Golden and Henderson, 2007;
Woszczek et al., 2005; Williams and Spector, 2009). Moreover, inhibitors of 5LOX and cysLT1 are used in the treatment of asthma (Israel et al., 1996; Schmidt
et al., 2005; Van Schoor et al., 1997).
5-LOX in concert with 15-lipoxygenase (15-LOX) or 12-lipoxygenase,
generates lipoxin A4 and lipoxin B4. Not only does lipoxin production decrease
leukotreine production, generally, the actions of lipoxins function to oppose the
actions of leukotrienes (Serhan, 2005). Lipoxins control the resolution of
inflammation by stimulating anti-inflammatory pathways such as inhibiting
neutrophil infiltration, acting as a chemoattractant for macrophages and
stimulating their uptake of apoptotic cells, and decreasing production of proinflammatory cytokines such as IL-1 and IL-8 (Papayianni et al., 1996; Godson et
al., 2000; Lee et al., 1989; Bonnans et al., 2002; Machado et al., 2008; Maddox
et al., 1997; Sodin-Semrl et al., 2000; Wu et al., 2005). These actions play a
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role in the resolution of inflammatory events such as airway inflammation,
asthma, arthritis, and gastrointestinal disease (Kronke et al., 2009; Serhan, 2005;
Janakiram and Rao, 2009; Levy et al., 2002; Wallace et al., 2005).
12/15-Lipoxygenase
In the process of metabolizing polyunsaturated fatty acids, 12/15lipoxygenase (12/15-LOX) generates multiple products. 12/15-LOX introduces
molecular oxygen into AA and linoleic acids to produce bioactive labile lipid
intermediates such as 12(S)-hydroperoxyeicosatetraenoic acid (12(S)-HpETE),
15(S)-hydroperoxyeicosatetraenoic acid (15(S)-HpETE) and 13(S)hydroperoxyoctadecadienoic acid (13(S)-HpODE). These intermediates are
rapidly reduced by glutathione reductase to release ROS and produce additional
bioactive lipid metabolites, including 12(S)-HETE, 15(S)-HETE, 13(S)-HODE,
lipoxins, and hepoxilins (Kuhn and O'Donnell, 2006) (Figure 5). 12/15-LOX can
also oxidize membrane-bound fatty acids directly to produce additional fatty acid
products. Moreover, novel products of 12/15-LOX are still being defined (Wei et
al., 2009).
Humans have multiple 12/15-lipoxygeneases, including leukocyte-type 12lipoxygenase, 15-lipoxygenase-1 and 15-lipoxygenase-2 all of which have the
ability to produce 12(S)-HETE as well as 15(S)-HETE albeit in different ratios.
15-Lipoxygenase-1 is expressed in reticulocytes, leukocytes, bronchial epithelial
cells and carcinoma cells while 15-lipoxygenase-2 is not expressed in peripheral
leukocytes but rather in liver, spleen, kidney, intestines, testis, ovary, muscle,
heart and brain. 15-Lipoxygenase-1 and 15-lipoxygenase-2 are co23
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expressed in bronchial epithelial cells (Chanez et al., 2002). Leukocyte-type 12lipoxygenase is expressed in leukocytes, liver, lung, and endothelial cells (Funk
et al., 1992). On the other hand, mice possess a single leukocyte-type 12/15lipoxgenase, which produces 12(S)-HETE and 15(S)-HETE at a ratio of 3:1
(Chen et al., 1994). Therefore, murine 12/15-LOX and human 12- and 15lipoxygenases differ in lipid mediator production. Some of the effects of murine
12/15-LOX are analogous to human leukocyte 12-lipoxgenase (Mullin et al.,
2007) while others map to 15-lipoxygenase-1 (Kelavkar et al., 2004). Therefore,
in order to elucidate the relevant human counterpart, it is important to understand
the products of murine 12/15-LOX that mediate its biological effects. Platelet-type
12-lipoxygenease and epidermal-type 12-lipoxygenase are additional
lipoxygenases found in humans and mice but are less related to leukocyte-type
12-lipoxygenase and 15-lipoxygenase-1 both by sequence and function.
12/15-Lipoxygenase products can activate multiple signaling pathways
resulting in activation of transcription factors including peroxisome proliferatoractivated receptor γ, IRF-8, and nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) that then modulate gene transcription (Huang et al.,
1999; Middleton et al., 2006a) (Figure 6). 12(S)-HETE and 15(S)-HETE both
activate protein kinase C (PKC) while 15(S)-HETE and 13(S)-HODE activate the
mitogen activated protein kinase (MAPK) pathway. Products of 12/15-LOX can
also be incorporated into cellular membranes to regulate cellular functions
(Takata et al., 1994; Kuhn and Brash, 1990; van Leyen et al., 1998). 12/15-LOX
lipid mediator signaling events have pleiotropic affects on myriad cell types.
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Notably, 12/15-LOX regulates the pathogenesis of atherosclerosis, psoriasis,
arthritis, glomerular nephritits, and airway inflammation (Conrad, 1999).
Reactive Oxygen Species
ROS are another important product of fatty acid metabolism. Cellular
ROS, such as superoxide O2-, hydrogen peroxides H2O2, hydroxyl radial OH- and
hypochlorous acid HOCl, are produced through the actions of nicotinamide
adenine dinucleotide phosphate oxidases (NAPDH oxidases), mitochondria and
fatty acid metabolism (Ghaffari, 2008; Haddad, 2002a). ROS regulate multiple
signaling processes. For instance, ROS play a paramount role during phagocyte
killing of bacteria in a process known as the oxidative burst. ROS can also be
highly toxic to cells by causing oxidative stress resulting in cellular and tissue
damage through oxidative modification of cellular components and activation of
apoptosis. Therefore, the levels of cellular ROS are tightly controlled by the
presence of anti-oxidants. Cellular anti-oxidants are present in various forms
including reducing agents such as vitamin E, vitamin C, glutathione and including
enzymes such as catalase, superoxide dismutase and peroxidases. For
example, superoxide is catalyzed by superoxide dismutase to produce hydrogen
peroxide H2O2, which is further metabolized by catalase to produce molecular
oxygen and water (Ghaffari, 2008). Inhibition of anti-oxidants in the cell can result
in oxidative stress (Jones, 2008).
ROS mediate redox reactions, which is the shuffling of electrons in
chemical reactions. Redox signaling is always occurring within the cell in
homeostatic conditions to regulate essential cellular functions. For instance,
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redox signaling in the electron transport chain in mitochondria generates the
majority of energy in the body as adenosine triphosphate (Hancock, 2009).
Redox signaling also regulates protein function. Cysteines within proteins contain
a thiol residue that is susceptible to oxidative modification, which can result in the
formation of disulfide bonds if two cysteine residues are in close proximity.
Oxidative modification of a protein residue can have multiple effects on protein
function. If the residue is in a catalytic site of an enzyme, oxidative modification
can cause functional inactivation. If the residue is in an allosteric site, oxidative
modification can alter protein conformation and function as a rheostat for protein
activity. Moreover, oxidative modification of proteins can alter protein binding and
result in decreased or increased binding to substrates such as DNA, membranes,
cytoskeleton or other proteins (Jones, 2008).
In theory, redox signaling can regulate any protein with an accessible
cysteine residue. There is an average of 1.9 cysteine residues per protein in
humans. Therefore, redox signaling could theoretically regulate many proteins.
Because of the need for cysteine residues to be accessible it is likely that only
10-20% of human proteins are in fact directly regulated by redox signaling
(Jones, 2008). Many protein targets of redox reactions have been identified
including receptors such as αIIbβ3 integrin, phosphatases such as SHP-1/2,
PTEN and protein phosphatase-1α (PP1α), cytoskeletal components such as
actin and signal transducers such as caspases, ras-related C3 botulinum toxin
substrate 1 (Rac1), IκB kinase (IKK) and kelch like-ECH-associated protein 1
(Keap1). Production of ROS mediates modulation of multiple signaling
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pathways including activation of p-53, Ras, PI3-K and p38 MAPK signaling and
modulation of gene transcription by NFκB, nuclear factor erythroid-derived-like 2
(Nrf2), Egr-1 (Haddad, 2002a; Hainaut and Mann, 2001; Iiyama et al., 2006;
Naughton et al., 2009; Pan et al., 2009). ROS signaling results in cellular
functions such as proliferation and secretion of inflammatory cytokines (Iiyama et
al., 2006) (Haddad, 2002b). On the other hand, hypoxia can result in migration of
macrophages and DC and activation of transcription factors including HIF1α,
HIF2α, activator protein-1 (AP-1), activating transcription factor-2/5 and Fos
homolog B (Bosco et al., 2008; Haddad, 2002a). This dissertation elucidates a
novel target downstream of redox signaling, the transcription factor IRF-8 and
implicates the redox sensitive phosphatase SHP-1/2 in this regulation.
Alox15 mice
Mice deficient in 12/15-LOX, Alox15 mice, have been developed by
targeted disruption of exon 3 to generate an in-frame stop codon prior to the
catalytic domain (Sun and Funk, 1996). Alox15 mice have been extensively
studied in the context of inflammation. For instance, Alox15 mice were protected
against atherosclerosis (Cyrus et al., 2001; George et al., 2001). This protection
was associated with decreased ox-LDL production in Alox15 macrophages (Sun
and Funk, 1996) and decreased IL-12p40 production in Alox15 atherosclerotic
lesions (Zhao et al., 2002). Alox15 mice were also protected against
inflammation caused by allergic asthma (Andersson et al., 2008; Hajek et al.,
2008) and acute lung injury (Zarbock et al., 2009). The attenuated inflammation
was associated with decreased levels of the 12/15-LOX product 12(S)-HETE
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(Zarbock et al., 2009). However, Alox15 mice exhibited exacerbated
inflammation in a tumor necrosis factor transgenic model of arthritis (Kronke et
al., 2009), which was associated with decreased levels of the anti-inflammatory
12/15-LOX-mediated product, LXA4. Therefore, the signaling downstream of
12/15-LOX depends on the production and context of specific 12/15-LOXgenerated products.
12/15-LOX promotes IL-12p40 production in macrophages. Alox15
peritoneal macrophages but not bone marrow derived dendritic cells exhibited
decreased levels of IL-12p40 in response to LPS and IFN-γ stimulation. This
defect was associated with decreased levels of IRF-8 and NF-κB binding to the
IL-12p40 promoter (Middleton et al., 2006a). Others also demonstrated that
12/15-LOX contributes to inflammatory gene expression in macrophages
(Dioszeghy et al., 2008). 12/15-LOX regulation of IL-12p40 and inflammatory
gene transcription in macrophages has implications for inflammatory diseases in
which macrophages play a predominant role. As stated previously, 12/15-LOXdependent IL-12p40 production contributed to the inflammatory milieu and
disease progression of atherosclerosis (Zhao et al., 2002). Moreover, Alox15
mice were defective in immunity to chronic toxoplasma gondii infection but not
during acute infection (Middleton in press) highlighting the selective role of 12/15LOX and macrophages during chronic inflammation. In this dissertation, I will
demonstrate that 12/15-LOX regulates IL-12p40 production in macrophages at
least in part through ROS signaling.
MPN in Alox15 mice
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In the course of studying Alox15 mice in the context of chronic
inflammation, our lab made the unexpected finding that Alox15 mice exhibit
increased mortality due to development of a CML- like MPN in about 10-15% of
the mice over the course of a year. The majority of Alox15 mice remained
asymptomatic and exhibited splenomegaly, basophilia, and an increased
percentage of granulocytes in blood and spleen. Alox15 Gr1+ splenocytes
exhibited increased proliferation and decreased cell death compared to wild-type.
Addition of the 12/15-LOX product 12(S)-HpETE increased cell death in both
Alox15 cells and the human K562 CML cell line (Middleton et al., 2006b).
Asympomatic Alox15 myeloid cells also exhibited increased phosphorylation of
the tyrosine kinase Akt, and decreased nuclear accumulation and transcriptional
activity of tumor suppresssor IRF-8. Meanwhile, the moribund mice exhibited a
MPD characterized by massive splenomegly, accumulated granulocytes in the
bone marrow, spleen, blood and skin and the presence of myeloid blasts. This
phase of disease was associated with the loss of IRF-8 gene expression
(Middleton et al., 2006b). Because a proportion of Alox15 mice develop a MPN, I
hypothesized that 12/15-LOX regulates myelopoieis. In this dissertation, I will
demonstrate that 12/15-LOX does indeed regulate myelopoiesis and elucidate
the mechanisms whereby this regulation occurs.
12/15-LOX in Hematopoiesis
Although the relationship between fatty acid metabolism and inflammation
in mature leukocytes has been extensively studied, little is known about the
contributions of fatty acid metabolism to hematopoietic development. During
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erythroid development in rabbits and humans, the 12/15-LOX products 15(S)HETE and 13(S)-HODE modulate membrane degradation, an important step in
erythroid differentiation (Kuhn and Brash, 1990; van Leyen et al., 1998). However
prior to my studies, the role of 12/15-LOX in murine erythroid development was
unknown.
Little was previously known about the role of 12/15-LOX and its products
in myeloid development. Addition of 12/15-LOX lipid products 12(S)-HETE and
15(S)-HETE to cultures of human CD34+ cells decreased the numbers of
granulocyte-macrophage colonies in methylcellulose assays (Desplat et al.,
2000). However the role of 12/15-LOX in granulocyte and monocyte
differentiation has remained unexplored. Data presented in this dissertation
demonstrate that 12/15-LOX promotes monocyte development.
As stated earlier, previous studies in our lab demonstrated that 12/15-LOX
is a novel suppressor of MPN (Middleton et al., 2006b). Approximately 15% of
Alox15 mice develop a severe MPN over the course of a year. Moreover, the lipid
mediators of 12-lipoxygenase are reduced in human CML (Stenke et al., 1991;
Stenke et al., 1987; Takayama et al., 1983) implicating 12/15-LOX in the
regulation of human disease as well. Although 12/15-LOX acts as a suppressor
of myeloid leukemogenesis, its role in normal myeloid development was not
previously known.
ICSBP/IRF-8, a critical regulator of lineage specification and immunity, is
regulated by 12/15-LOX. Our lab previously demonstrated that IRF-8 DNA
binding and nuclear accumulation were compromised in Alox15
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macrophages and splenocytes (Middleton et al., 2006a; Middleton et al., 2006b).
This resulted in decreased IL-12p40 transcription in Alox15 macrophages
(Middleton et al., 2006a) and in a CML-like myeloproliferative disorder in Alox15
mice (Middleton et al., 2006b). IRF-8 was shown in these studies to be regulated
by 12/15-LOX in part through phosphoinositide 3-kinase (PI3-K). PI3-K activity as
measured by pAKT levels was increased in Alox15 BM-derived cells and
inhibition of PI3-K resulted in increased nuclear accumulation of IRF-8 and
restored gene transcription (Middleton et al., 2006b). Because 12/15-LOX
regulates IRF-8 in mature myeloid cells, I hypothesized that 12/15-LOX also
regulates IRF-8 in immature myeloid cells. Moreover, because IRF-8 is important
to the development of multiple hematopoietic lineages, I hypothesized that 12/15LOX may also regulate hematopoiesis by promoting ICSBP/IRF-8 nuclear
accumulation and transcriptional activity.
ROS in Hematopoiesis
ROS, which are functional by-products of 12/15-LOX activity (Conrad,
1999), are known to regulate HSC function. Low levels of ROS maintained
through interactions in the osteoblastic HSC niche are critical for LT-HSC
function (Jang and Sharkis, 2007). The oxidative state of HSCs is also regulated
in part by NAPDH-oxidases (Piccoli et al., 2007). However, the role of
lipoxygenase-generated ROS has not yet been defined in HSC.
Increased levels of ROS can signal through p38 MAPK to cause defective
HSC quiescence and self-renewal. Treatment of normal bone marrow with
buthionine sulfoximine (BSO), which increases ROS by inhibiting synthesis
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of the anti-oxidant gluthathione, increased p38 MAPK specifically in HSC and
inhibited the ability of HSC to reconstitute lethally irradiated mice (Ito et al.,
2006). Levels of ROS increased in HSC during serial transplantations and
treatment with the anti-oxidant N-acetylcysteine (NAC) or with a p38 MAPK
inhibitor extended the self-renewal ability of serial reconstituted HSC (Ito et al.,
2006). Deletion of the DNA repair enzyme ataxia telangiectasia mutated (ATM)
increased levels of cellular ROS, decreased quiescence and increased p38
MAPK activation in the HSC. This resulted in a defect of ATM-deficient HSC to
reconstitute lethally irradiated mice. Treatment with a p38MAPK inhibitor
(SB203580) restored HSC quiescence and function (Ito et al., 2006). ROS in
HSC were also increased when members of the forkhead box subgroup O
(FoxO) transcription factor family (FoxO1/3/4) were deleted. Similar to ATMdeficient HSC, FoxO-deficient HSC exhibited increased levels of ROS,
decreased quiescence and a defect in the ability to reconstitute lethally irradiated
mice. Treatment with the anti-oxidant NAC restored HSC quiescence and
function (Tothova et al., 2007). The perturbed HSC function associated with
FoxO deletion was also associated with activation of p38 MAPK. Moreover,
FoxO3a-deficient HSC exhibited similar defects as FoxO1/3/4-deficient HSC.
FoxO3a-deficient HSC exhibited increased activation of p38MAPK and treatment
with a p38MAPK inhibitor restored HSC function in this mouse model (Miyamoto
et al., 2007).
The tuberous sclerosis complex (TSC)-mammalian target of rapamycin
(mTOR) pathway also functions in HSC to suppress ROS production and
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promote HSC quiescence and self-renewal. When TSC was conditionally deleted
in hematopoietic cells, the HSC exhibited increased proliferation and defective
self-renewal. These defects were accompanied by an increase of ROS in the
HSC in part by increasing mitochondrial biogenesis. Treatment with the antioxidant NAC restored HSC function (Chen et al., 2008). Hence, accumulation of
ROS negatively impacts HSC function and self-renewal in multiple mouse
models. In this dissertation, I demonstrate that Alox15 HSC exhibit increased
basal levels of ROS but decreased levels of ROS in response to AA that is likely
12/15-LOX-dependent. The increased basal levels of ROS in Alox15 HSC may
contribute to their defective self-renewal and quiescence.
ROS may also have effects on myeloid cell fate decisions. ROS mediate
cytokine receptor signaling, including in response to GM-CSF. Addition of ROS in
the form of hydrogen peroxide increased tyrosine phosphorylation of cytokine
receptors and signal transducers while addition of anti-oxidants had the converse
effect (Iiyama et al., 2006; Sattler et al., 1999). Moreover, ROS generated by
dominant negative NF-κB inhibits granulocyte differentiation, which was restored
by addition of an anti-oxidant (Nakata et al., 2004). However, this study did not
examine the effects on mature monocyte development. In this dissertation, I
demonstrate that ROS mediate monocyte development in Alox15 mice.
Summary
In summary, in the following chapters I will describe novel functions for
12/15-LOX in hematopoietic development. Because a percentage of Alox15 mice
develop a myeloproliferative disorder, I hypothesized that 12/15-LOX
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regulates hematopoietic development. To test this hypothesis, I characterized
hematopoietic subsets in wild-type and Alox15 mice. I found that 12/15-LOX
regulates HSC function and monocyte development. For my dissertation, I
elucidated the mechanisms whereby this regulation occurs. An overview of my
dissertation is shown in Figure 7.
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EXPERIMENTAL METHODS
Mice- C57BL/6 (B6) and Alox15 mice (backcrossed to B6 11 generations)
purchased from Jackson Laboratories, were housed and bred in the animal
facility of the Wistar Institute. Mice were used between 8-10 weeks of age prior to
the onset of MPD except where explicitly stated. Congenic B6.SJL mice were
obtained from Taconic or NCI. All animal procedures were approved by Wistar
Institute institutional care and animal use committee.
Hematologic analysis- Whole blood obtained via submandibular bleeding diluted
with 1% PBS/PBS with 5 µL of 0.5 M EDTA. Blood was analyzed on an
Advia2120 hematology analyzer in the mouse mode (Siemens Healthcare
Diagnostics).
Fetal liver isolation-Two female mice and 1 male mouse were placed in a cage
overnight. Mice were then separated by sex and pregnant mice were sacrificed
14 days later to isolate fetal liver from day 14.5 embryos.
Macrophage isolation-To generate bone marrow derived macrophages, bone
marrow from wild-type and Alox15 mice were isolated from the long bones. Cells
were subject to RBC lysis using ammonium chloride and were cultured at 1x106
cells per ml, in 10 ml of 10% L292 supernatant in RPMI containing 10% fetal calf
serum (FCS), 50µM β-Mercaptoethanol, 1% penicillin, streptomycin and
fungizone on untreated 10cm2 tissue culture plates. After 5 days, non-adherent
cells were washed away and purity was checked by flow cytometry. Cells were at
least 85-90% macrophages by F4/80+ staining and flow cytometric analysis.
To isolate thioglycolate-elicited macrophages, B6 and Alox15 mice were
38

injected intraperitoneally with 2ml sterile 3% Brewer’s thioglycollate broth (SigmaAldrich). Four days later macrophages were isolated peritoneal cavity with PBS.
Cells were plated for 2 hours to overnight in 10% FCS in RPMI containing 50µM
β-Mercaptoethanol, 1% penicillin, streptomycin and fungizone. Non-adherent
cells were washed away. The remaining cells were at least 90% pure by F4/80+
staining and flow cytometric analysis.
Flow cytometry- Single cell suspensions were prepared from thymus, spleen,
fetal liver and BM isolated from tibia and fibulas. RBC were lysed using
ammonium chloride except for erythroid progenitor analysis.
Immunocytochemistry reagents were obtained from the following sources: cKit,
Invitrogen; CD34, CD45.1, Biolegend; CD3, IgM, Gr1, streptavidin-conjugates,
BD Bioscience; all others, eBioscience. Differentiated cells were depleted with a
cocktail of antibodies directed against: Gr-1, B220, CD3, IL-7Rα, Ter119, NK1.1,
Mac1 and CD11c; anti-IL7Rα was omitted when analyzing CLP, ETP, DN2 and
DN3. Cells were resuspended for staining in 1%BSA/PBS and blocked for
nonspecific staining using murine IGG (Jackson ImmunoResearch) for 5 minutes
room temperature before addition of antibodies. Cells were stained for 30
minutes at 4C and washed with PBS. Secondary antibody staining was in
phosphate buffered saline (PBS) for 30 minutes at 4C. Cells were analyzed by
flow cytometric analysis on a FACS Calibur or LSR II using Flowjo software
(Treestar).
Cell cycle analysis- Bone marrow was isolated and stained at 1x106 cells/ml in
2% FCS RPMI with 10 µg/ml Hoechst 33342 at 37C incubator for 45 minutes
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followed by addition of 300 ng/ml PyroninY (Sigma-Alrich) for an additional 45
minutes. Cells were then washed with cold PBS and kept at 40C for subsequent
multicolor flow cytometric analysis to identify progenitor populations. In some
experiments, bone marrow was treated for 45 minutes or overnight with
increasing concentrations of 12(S)-HETE or 15(S)-HETE (Cayman Chemical).
AnnexinV and TUNEL staining- For AnnexinV staining, cells were stained for
multicolor flow cytometry prior to incubation with 5 µl AnnexinV-FITC (Invitrogen)
in 100 µl AnnexinV staining buffer for 10 minutes at room temperature after which
400 µl additional staining buffer was added.
In situ staining kit for Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) was obtained from Roche. Staining was performed
according to manufacturer’s protocol. Treatment with DNAse was used as a
positive control while fluorescence minus one (FMO) (without fluorescein-dUTP)
was used as a negative control.
Bone marrow reconstitution and 5-FU assays -Recipient mice were irradiated
with 1000 rads of γ irradiation from a Cesium J. L. Sheppard Mark irradiator.
Mice were transplanted with 1.8x106 test: 2x105 competitor BM cells (9:1),
2x105:2x105 competitor BM cells (1:1), 1x106 E14.5 fetal liver cells: 0.5x106
competitor BM cells (2:1) and 0.5x106 E14.5 fetal liver cells: 0.5x106 competitor
BM cells (1:1) for competitive reconstitution assays and 1x106 BM cells for
noncompetitive and serial reconstitution assays. Mice were injected i.p. with 200
mg/kg 5-FU (Roche) to determine self-renewal ability.
Cell separation-Lin-cKit+ cells were obtained using MACS separation kit
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(Miltenyi-biotech). Briefly, cells were resuspended in 40 µl MACS Buffer (0.5%
BSA 2 mM EDTA PBS pH 7.2) per 107 cells and 10 µL of lineage antibodies were
added per 107 cells. Cells were incubated for 10 minutes at 4oC prior to addition
of 30 µL MACS buffer per 107 cells and 20 µL anti-biotin microbeads. Cells were
then incubated for an additional 15 minutes prior to washing with PBS. Cells
were resuspended with 500 µL MACS buffer per 108 cells and the negative
fraction was obtained on LS columns. For some experiments, cKit microbeads
were used subsequent to the Lin- purification. Cells were counted and
resuspended in 80µl MACS buffer per 107 cells and 20 µL cKit microbeads were
added per 107 cells. Cells were incubated for 15 minutes prior to washing and the
positive fraction was collected on MS columns. In all experiments, purity was
checked using flow cytometric analysis and determined to be at least 90% pure.
Immunoblotting- Nuclear extracts were prepared using Nucbuster kit (EMB
Biosciences) from Lin-cKit+ cells pooled from 3 mice and from bone marrowderived macrophages. MPER was used to obtain total (cytoplasmic and nuclear)
cell lyates. Lysates were normalized to total protein using Bradford assay
(Pierce) and resolved by 7.5% SDS PAGE, transferred to PVDF membranes,
and immunoblotted with antibodies specific for ICSBP/IRF-8, Dab2, Rb, 12/15LOX (Santa Cruz Biotechnology) and β-catenin (BD Bioscience). Peroxidaseconjugated secondary antibodies were obtained from Jackson Immunoresearch.
ROS and lipid analysis- ROS levels were analyzed on LSK enriched by cell
sorting and on BMM by loading with 10 µM CM-H2DCFDA (Invitrogen) in the
presence (LSK) or absence (LSK, BMM) of 10 µM AA (Cayman Chemical)
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(LSK) for 30 min at 37°C. Cells were then analyzed by flow cytometry. For lipid
analysis, BM, Lin- enriched cells and BMM were loaded for 30 minutes with 10
µM AA (Cayman Chemical), the supernatants were extracted and analyzed by
stable isotope dilution normal phase chiral liquid chromatography coupled with
electron capture atmospheric pressure chemical ionization/mass spectrometry.
Cell sorting and quantitative-PCR-BM cells from 3-5 mice were pooled, stained
and sorted on an Aria cell sorter at the University of Pennsylvania or Wistar
Institute flow cytometry facility. mRNA was isolated using RNeasy microRNA kit
(Qiagen) and cDNA synthesized using reverse transcriptase. Quantitive real time
PCR was performed with Syber green master mix in an ABI 7000 cycler (Applied
Biosystems) and normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) levels. Primer sequences were designed using Primer Express
(Applied Biosystems).
Primer Sequences
Gapdh (forward) 5′−G A C G G C C G C A T C T T C T T G T and (reverse) 5′−C
A C A C C G A C C T T C A C C A T T T T-3′; β- actin, (forward) 5′−T C A G C A
A G C A G G A G T A C G A T G -3′ and (reverse) 5′−A A C A G T C C G C C T
A G A A G C A C T T-3′; Icsbp/Irf8 (forward) 5′T G G G C A G T T T T T A A A G
G G A A G T T-3′ and (reverse) 5′-A C A G C G T A A C C T C G T C T T C C A 3′; 12/15- Lox (forward) 5′-A C C C C A C C G C C G A T T T T and (reverse) 5′A G C T T C G G A C C C A G C A T T T; Dab2(forward) 5′−G G C C A C A C C
G C C T C A A- 3′(reverse) 5′−A G C G T C A C T G G G A A T G T C C T T-3′;
Nf1 (forward) 5′−G G T A T G G A C A C A G G A C C T C T A G G A T-3′
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and (reverse) 5′−C T G C G G G T A C C A T G A A G C A-3′; Blimp1 (forward)
5′−G G A G G A T C T G A C C C G A A T C A-3′ and (reverse) 5′−T C C T C A
A G A C G G T C T G C A T T G-3′; p15Ink4b(forward) 5′−T G G G T G G G T G
C A G T C A G T A C-3′ and (reverse) 5′−T C C C A T T T A G C C T G T G G A
T C A-3′; Hes-1 (forward) 5′−T C A G C G A G T G C A T G A A C G A-3′ and
(reverse) 5′−T G C G C A C C T C G G T G T T A A C-3′; Bmi (forward) 5′−T T C
C G C C C G C T C A G A T C-3′ and (reverse) 5′−C G A T G C A T T T C T G C
T T G A T A A A A-3′; Hoxb4 (forward) 5′−G A A G G A A G C A A G A A A A G
G A G G A A-3′ and (reverse) 5′−G A T T A A A G A T G A A G C C T G G A T C
C A T-3′; Gfi1 (forward) 5′−T G C T C C G A G T T C G A G G A C T T-3′ and
(reverse) 5′−C A G A G A G C G G C A C A G T G A C T T-3′; PU.1 (forward) C
C G G A T G T G C T T C C C T T A T C and (reverse) T C T A C C C T C C T C
C T C A T C T G A; C/EBPα (forward) G A C C A T T A G C C T T G T G T G T
A C T G T A T G and (reverse) T G G A T C G A T T G T G C T T C A A G T T;
Egr-1 (forward) C C A T G A A C G C C C A T A T G C T T and (reverse): G C T
CATCCGAGCGAGAAAAG
Methylcellulose assays- 1.5x105 splenocytes, 1.5x104 bone marrow cells, 500
sorted LSK and CMP and 1000 GMP and MEP were plated in methylcellulose
containing IL-3, IL-6, SCF and EPO (M3434, Stem Cell Technologies). In other
methylcellose assays, 5x105 wild-type or Alox15 bone marrow cells were plated
in methylcellulose (M3234, Stem Cell Technologies) after addition of 10 ng/ml MCSF, G-CSF, GM-CSF or IL-3 (Peprotech). After 10 days, colonies were
enumerated using light microscopy in a blinded fashion. In some assays, 1
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µM 12(S)-HETE (Cayman Chemical), 10 µM or 50 µM NSC-87877 (EMD
bioscience) or 0.025 µM BSO (Sigma) were added to the methylcellulose at the
time of plating.
Rapamycin treatment- Rapamycin (LC, laboratories) was dissolved in absolute
ethanol into 50 mg/ml stock and then further diluted in 5% Tween-80 (Sigma) and
5% PEG-400 (Sigma). Mice were injected intraperitoneally with 4 mg/kg
rapamycin or vehicle control in a 200 µl volume daily for 7 days.
Retroviral Studies- MigR retrovirus was obtained from Dr. W. Pear (University of
Pennsylvania). Mutated nondegradable Beta-catenin MSCV was obtained from
Dr. T. Reya (Duke University). 12/15-LOX in the MigR retroviral construct was
constructed by introducing a Bgl II site using PCR amplification of a plasmid
containing 12/15-LOX (C. Funk) followed by subcloning into Topo vector
(Invitrogen). The MigR vector and the 12/15-LOX Topo plasmid were digested
overnight with Bgl II and XhoI, purified and ligated. Sequence of 12/15-LOX was
verified by sequencing (University of Pennsylvania).
To make the retroviral particles, 293T cells were plated at 2x106 cells/plate
into 6 cm plates in 3 ml. The next day, the media was replaced with warm media
containing 25 mM chloroquine. The transfection cocktail was prepared in 1.7ml
eppendorf tubes in 500 µl total volume in sterile water: 50 µL 2.5 M CaCl2, 5 µg
pCL-Eco packaging vector (Imgenex), 10 µg retroviral plasmid. 500 µL HEPESbuffered saline HeBS (2X: 50 mM HEPES, 10 mM KCl, 12 mM Dextrose, 280
mM NaCl, 1.5 mM Na2HPO4 at pH 7.1 filtered and frozen aliquots at -20oC) was
added drop-wise with a 1 ml serological pipette and then bubbled and
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vortexed for 10 seconds each. The cocktail was slowly added to the side of the
dish. After 5-7 hours, cells were washed and medium replaced. Medium was
replaced again the following day. At 48 hours post-transfection, viral particles
were isolated from the supernatant, filtered through a 0.45 µM syringe and
aliquots stored at -80oC. Titer was checked on 3T3 cells grown at 1x106 overnight
in 6 cell plates. 100 µL supernatant and 2 µg/mL polybrene was added and titer
checked for GFP expression by flow cytometry 48-72 hours post-transduction.
For retroviral transduction, B6 and Alox15 E14.5 fetal liver cells were
isolated and stimulated with 50 ng/ml SCF, 10 ng/ml IL-3 and IL-6 (Peprotech) at
2-3x106 cells/ml in 4 ml 20% FCS RPMI in 6 well plates. After overnight
incubation, 0.5-1 ml was taken, spun and replaced with 0.5-1 ml retroviral
supernatant and 4 µg/ml polybrene (Sigma) was added. Cells were spun for 90
minutes at 2750 rpm and then put in an incubator overnight. The next day, the
transduction procedure was repeated. Fetal liver cells were determined to be
retrovirally tranduced by the expression of GFP in a percentage of the cells at
day 3 in culture. Cells were at least 30% GFP+. On either day 2 or day 3, cells
were washed 3X, counted and at least 1x106 cells were injected via tail vein in
200 µl PBS into lethally irradiated mice (900 rads). For sublethal irradiation, 400700 rads were used.
Statistical Analysis- One-way ANOVA, t-tests, or Mann-Whitney were applied
using Graphpad Prism software or Excel as indicated for each data set. Results
in which p<0.05 were considered statistically significant for all tests
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CHAPTER 1: Alox15 mice exhibit alterations in hematopoietic
compartments
Hematopoiesis is the process whereby all the cells of the immune system
develop. It is a tightly regulated process orchestrated by a balance of
transcription factor and cytokine signaling that results in defined numbers of
blood cell populations including lymphoid, erythroid, and myeloid cell lineages.
HSCs are the only cells with both the ability to self-renew and to differentiate into
all blood cell types. As cells further differentiate they become more limited in their
differentiative capacity. Dysregulated hematopoiesis can result in leukemias,
anemias or immunodeficiencies. Therefore, it is important to elucidate pathways
that contribute to normal hematopoiesis. Although much is known about
transcription factors that regulate cell fate decisions during hematopoietic
development, less is known about signaling pathways that govern hematopoietic
cell specification.
Although fatty acid metabolism has been extensively studied in the context
of chronic inflammation mediated by hematopoietic cells, the role of fatty acid
metabolism in general during hematopoietic development is not well understood.
In the process of studying the role of 12/15-LOX-mediated fatty acid metabolism
in the context of chronic inflammation, our lab discovered that a proportion of
Alox15 mice, which lack 12/15-LOX, developed a CML-like disease over the
course of a year. Moreover, the majority of Alox15 mice which lacked the CMLlike disease were referred to as “asymptomatic” and exhibited an increased
percentage of Mac1+Gr1+ cells in the blood, spleen and bone marrow (BM)
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(Middleton et al., 2006b). However, other hematopoietic compartments within
Alox15 mice were not studied in depth. Because Alox15 mice exhibited an
increased percentage of granulocytes and developed a leukemia, I hypothesized
that 12/15-LOX regulates hematopoiesis. To formally test this hypothesis, I
characterized the hematopoietic subsets in wild-type and Alox15 mice. This
chapter describes the multiple hematopoietic defects in Alox15 mice which
demonstrates that 12/15-LOX does indeed regulate hematopoiesis.
Alterations in WBC compartment
To establish the impact of 12/15-LOX deletion on the peripheral
hematopoietic compartment, we performed hematologic analysis of peripheral
blood from “asymptomatic” 12-15 week old Alox15 and B6 mice. Alox15 mice
exhibited a lower white blood cell (WBC) count, largely attributable to a reduction
in lymphocytes and monocytes. Although the number of eosinophils and
neutrophils were similar, they accounted for a greater percentage of total cells in
Alox15 mice. The absolute number of basophils in asymptomatic Alox15 mice
was increased as noted previously (Figure 8A; (Middleton et al., 2006b).
To dissect the reduction in lymphocytes in Alox15 mice, we examined
mature lymphoid populations in the spleen and lymphoid development in BM and
thymus. The reduction in mature lymphocytes was mainly attributed to a
reduction in B cells in the spleen (Figure 8B). Moreover, B cell development in
the BM was defective in Alox15 mice. Although the percentage of earliest B
lineage progenitors, including LSK (Lin-Sca1+cKit+), common lymphoid
progenitors (CLP: Lin-IL-7Rα+cKitloSca1lo) and preproB (B220+CD43+HSA47

CD19-) cells were similar between wild-type and Alox15, the percentage of proB
(B220+CD43+HSA+CD19+) and preB (B220+CD43-IgM-CD19+) cells were reduced
in Alox15 BM (Figure 8C). We also observed a less dramatic but significant
defect in T cell development. Double-positive thymocytes (CD4+CD8+) were
decreased in Alox15 compared to B6, but early thymic progenitors (ETP: LinCD25-cKit+), DN2 (Lin-CD25+cKit+) and DN3 (Lin-CD25+cKit-) were similar (Figure
8D).
We next determined whether the defects in the WBC compartment were
also defective in younger (6 week), and older (26-30 weeks) mice using
hematologic analysis of peripheral blood. Indeed the alterations in WBC,
lymphocytes, monocytes and basophils were detected at multiple ages (Figure
9). Moreover, hematologic analysis of the subset of Alox15 mice exhibiting a
CML-like MPN, demonstrated increased numbers of WBC compared to
asympomatic Alox15 mice between 26-30 weeks of age. This increase was due
primarily to an increase in neutrophils, which confirms the CML-like MPD in these
mice (Figure 9).
12/15-LOX regulates RBC development
As 12/15-LOX regulates erythroid development in rabbits and humans, we also
investigated whether 12/15-LOX regulates murine erythroid development. Alox15
mice exhibited a decrease in red blood cells (RBC) and a concomitant increase
in reticulocyte number at 12-15 weeks of age. Moreover, hemoglobin (HGB) was
decreased while mean cell volumes (MCV) of the RBC were increased, indicating
that Alox15 mice developed a macrocytic anemia
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(Figure 10A). ***
Because RBCs were decreased in Alox15 mice, we determined the
percentage of erythroid progenitors in the BM and the spleen using Ter119 and
CD71 (transferin receptor) erythroid markers. Despite the decrease in mature
RBC, Alox15 erythroid progenitors were expanded, particularly in the spleen, the
major site of stress erythropoiesis in mice (Figure 10B). Both proerythrocytes
(CD71+Ter11lo) and erythrocyte progenitors (Ter119hi) were expanded. To
determine at which point the defect in RBC development occured, I compared
the frequency of B6 and Alox15 cells in erythroblasts fractions A, B and C using
CD71 and forward scatter after gating on the Ter119+ progenitors. As
erythroblasts develop they exhibit high forward scatter (size) and elevated levels
of CD71 (transferrin receptor), which participates in iron transport (Fraction A).
As the erythroid progenitors mature, they uptake iron and condense their
membranes leading to decreased forward scatter (Fraction B). Eventually the
erythroid cells are condensed and lose CD71 expression (Fraction C). Alox15
BM and spleen had increased fraction A, and the Alox15 spleen exhibited an
increase in fraction B compared to wild-type. However, there was a comparable
percentage of cells in fraction C between wild-type and Alox15 BM and spleen
suggesting a block in erythroid differentiation at this stage (Figure 10C). The
defect in RBC development likely occurs at the erythroblast B-C transition.
These data are consistent with the reported expansion of splenic red pulp
in Alox15 mice (Middleton et al., 2006b). Therefore, I examined H&E stained
splenic sections from wild-type and Alox15 mice to identify whether the
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expansion of the red pulp was due to the presence of erythroid progenitors.
Indeed, Alox15 spleens contained an abundance of erythroid progenitors, which
are identified as darkly stained cells, that are relatively absent in wild-type
spleens (Figure 11A-B). The presence of erythropoiesis was also demonstrated
by megakaryocytes, which were observed in the spleens of Alox15 but not wildtype (Figure 11C). In Alox15 mice with MPN, there was a complete loss of
splenic architecture and accumulation of mature and immature granulocytes as
previously reported (Figure 11D) (Middleton et al., 2006b).
Alterations in RBC parameters were defined in both young and old mice
by hematologic analysis. Both young (6 week) and older (26-30 week) Alox15
mice exhibited decreased RBC and HCT. In addition, older Alox15 mice (26-30
week) exhibited a decrease in platelet count (Figure 12). We also determined the
cellular subsets in the blood of the approximately 15% of Alox15 mice over the
course of a year that were moribund (Middleton et al., 2006b). This analysis
indicated there was a severe decrease in RBC and hematocrit (HCT) as the
Alox15 mice progressed from the asymptomatic syndrome to the more
aggressive disease (Figure 12).
No significant hematopoietic defects in Alox15 heterozygous mice
We also characterized the hematopoietic compartment of Alox15
heterozygous mice. First we determined that the splenocytes of heterozygous
Alox15 mice express roughly half as much 12/15-LOX as wild-type and hence
12/15-LOX is expressed in a gene dose-dependent manner (Figure 13A).
However, based on hematological analysis of peripheral blood subsets, there
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were no significant defects in the hematopoietic compartment (Figure 13B-C).
This may be due to small numbers (n=4) and variability in age of the mice (5-12
weeks). Nonetheless, no significant differences were detected in WBC (Figure
13B) or RBC (Figure 13C) parameters.
Defects in Alox15 mice are cell-autonomous
To determine whether the defects in Alox15 mice were cell-autonomous,
we performed adoptive transfer studies to define whether the phenotype was
inherent to BM-derived cells and/or dependent on the host environment. B6 or
Alox15 donor BM cells were engrafted into lethally irradiated congenic wild-type
recipients. At 16 weeks post-engraftment, recipient mice reconstituted with
Alox15 cells had decreased total WBC, lymphocytes and RBC in peripheral blood
compared to mice reconstituted with B6 BM (Figure 14A), analogous to the
defects observed in cells from Alox15 mice. Conversely, when congenic wild-type
(B6.SJL) BM was used to reconstitute B6 or Alox15 mice, there were no
differences in total or differential white blood counts (Figure 14B). These data
indicate that 12/15-LOX regulates hematopoiesis in a cell-autonomous manner.
Implications
Through the comparison of peripheral hematopoietic subsets in wild-type
and Alox15 mice, we demonstrate that 12/15-LOX regulates multiple
hematopoietic subsets in a cell-autonomous manner. However, although we
demonstrate the the phenotype of the blood cell subsets of track with the
genotype of the reconstituted bone marrow, it is possible that a subset of bone
marrow cells function in a paracrine manner to regulate blood cell
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development. We more definitely demonstrate that the defect in blood cell
development is cell-intrinsic hematopoietic stem cells using competitive
reconstitution assays in Chapter 2 of this dissertation. 12/15-LOX regulates T cell
differentiation at the DP stage, B cell differentiation at the propreB cell stage,
RBC generation, monocyte number and limits the number of basophils (Figure
15). The presence of multiple hematopoietic defects in the Alox15 mice suggests
that 12/15-LOX may regulate a common progenitor such as the hematopoietic
stem cell. The role of 12/15-LOX in hematopoietic stem cell function will be
discussed in Chapter 2.
Although these data suggest that 12/15-LOX may regulate a common
progenitor such as the HSC, it is also possible that 12/15-LOX may
independently directly regulate multiple hematopoietic subsets. These
possibilities are not mutually exclusive and our data as well as previous findings
suggest that both these possibilities do in fact simultaneously occur. Our data
imply that 12/15-LOX may possibly regulate development of B and T
lymphocytes, erythrocytes, and monocytes by distinct mechanisms by which it
regulates HSC function.
The mechanism whereby 12/15-LOX regulates B and T cell development
remains to be elucidated. Interestingly, 12/15-LOX had not been previously
shown to regulate lymphoid cell populations though its products were found in
the thymus (Harizi et al., 2008). Interestingly, IRF-8, which we demonstrated is
regulated by 12/15-LOX, had been shown to regulate B cell development at the
same stage of development that is defective in Alox15 mice (pro-preB cell
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stage) (Lu et al., 2003). However, whether 12/15-LOX regulates B cell
differentiation through IRF-8 is currently unknown and is a potentially interesting
future direction.
The defect in late stage erythroid differentiation in Alox15 mice is in
concordance with previous observations that a functional homolog of 12/15-LOX,
15-LOX, and its specific products, 15(S)-HETE and 13(S)-HODE, in other
species regulate reticulocyte maturation by modulating membrane degradation
(Kuhn and Brash, 1990; van Leyen et al., 1998). 12/15-LOX had not been
previously shown to regulate RBC development in mice and this is the first study
that establishes its role in murine erythroid cell differentiation. To more fully
understand the development of the macrocytic anemia in Alox15 mice, it would
be an interesting future direction to elucidate the mechanism whereby 12/15-LOX
regulates murine reticulocyte maturation.
There were decreased blood monocytes in Alox15 mice suggesting that
12/15-LOX may regulate monocyte development and myelopoiesis. The role of
12/15-LOX in myeloid cell development is of interest because of the potential
implications for CML and will be addressed further in Chapter 3 of this thesis.
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CHAPTER 2: 12/15-LOX is a critical regulator of LT-HSC self-renewal
The presence of multiple hematopoietic defects in Alox15 mice, detailed in
Chapter 1, suggests two possibilities, either of which are plausible and not
necessarily mutually exclusive. The first possibility is that 12/15-LOX regulates
multiple stages of hematopoiesis independently. The second possibility is that
12/15-LOX regulates a common hematopoietic progenitor such as HSC. The
data presented in this and subsequent chapters demonstrate that both these
possibilities occur. Specifically, I will present data in Chapter 3 which
demonstrate that 12/15-LOX drives myelopoiesis by promoting ICSBP/IRF-8
nuclear accumulation through redox signaling. In this chapter, I will present data
which demonstrate that 12/15-LOX regulates HSC function and self-renewal in
associated with modulation of canonical Wnt signaling.
The signaling pathways that govern the complex processes of HSC
function are not completely understood. HSCs are relatively rare yet must
produce billions of new cells daily and be able to adjust their output to respond to
environmental stresses such as infection, chemotherapy, blood loss, injury, etc.
To accomplish this, HSCs must divide asymmetrically by balancing self-renewal
and differentiation. Skewing of asymmetric division results in defective HSC
function. Decreases in numbers, alterations in the balance of asymmetric division
and increased proliferation decreases the ability of HSC to function (Ficara et al.,
2008; Nemeth et al., 2006; Passegue et al., 2005). Although much is known
about transcription factors that regulate these processes, such as Gfi-1, Bmi-1,
Hox4b and Pu.1 (Hock et al., 2004; Iwama et al., 2004; Iwasaki et al., 2005;
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Sauvageau et al., 1995), little is known about the signaling pathways that
regulate HSC function. Canonical Wnt signaling is one known pathway that
regulates HSC function by maintaining quiescence and initiating a self-renewal
program of gene transcription (Fleming et al., 2008; Zhao et al., 2007; Luis et al.,
2009). In this chapter, I determine that 12/15-LOX is a novel regulator of
canonical Wnt signaling which in turn may regulate HSC function by maintaining
quiescence and self-renewal.
Products generated by 12/15-LOX have been implicated in hematopoiesis.
ROS, which are generated as a product of 12/15-LOX fatty acid metabolism, can
impair HSC function by ROS-dependent regulation of the p38 MAPK pathway (Ito
et al., 2006). Moreover, 12/15-LOX generated lipid products, 12(S)-HETE and
15(S)-HETE, can inhibit differentiation of human CD34+ hematopoietic
progenitors in methylcellulose assays (Desplat et al., 2000). However, a role for
12/15-LOX per se has not been previously established in hematopoietic
development and HSC function.
In this chapter, I define 12/15-LOX as a critical regulator of LT-HSCs.
12/15-LOX regulates HSCs by promoting quiescence and self-renewal. Defective
HSC function in Alox15 mice is associated with defects in select products of
12/15-LOX including 12/15-LOX-generated ROS, 12(S)-HETE and 13(S)-HODE.
12/15-LOX regulates nuclear ICSBP/IRF-8 accumulation in hematopoietic
progenitors, which results in altered expression of ICSBP/IRF-8 target genes,
including increased production of Dab2, a negative regulator of canonical Wnt
signaling. Consequently, canonical Wnt signaling measured by its
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downstream mediator, β-cantenin, is disrupted in Alox15 progenitors. Thus, we
have defined 12/15-LOX as a novel regulator of LT-HSC function and canonical
Wnt signaling.
Alox15 mice exhibit a primary defect in HSC function
To test the possibility that 12/15-LOX regulates HSC function, we needed
to determine expression of 12/15-LOX in HSC. Using real time PCR analysis, we
determined that 12/15-LOX mRNA was expressed in wild-type HSC isolated by
cell sorting (Figure 16A). Moreover, 12/15-LOX protein was expressed in B6 (but
not Alox15) Lin-cKit+ hematopoietic progenitors by immunoblot (Figure 16B).
HSC function can be assessed by the ability to reconstitute the
hematopoietic compartment of a lethally irradiated animal. Competitive
reconstitution experiments, in which BM from control and experimental mice are
mixed with wild-type BM and injected into lethally irradiated mice, are based on
two assumptions: that HSC numbers and homing of the HSCs are similar
between control and experimental BM cells. LSK were present in similar numbers
in B6 and Alox15 BM (Figure 16C). Moreover, B6 and Alox15 BM cells homed
with comparable efficiency to both normal and lethally irradiated recipient BM
(Figure 16D). It was therefore appropriate to proceed with competitive
reconstitution assays.
To elucidate whether 12/15-LOX regulates early hematopoietic
progenitors such as the HSC, we set up competitive reconstitutions in which B6
or Alox15 BM cells (CD45.2) were mixed 9:1 with wild-type competitor B6.SJL
BM cells (CD45.1) and engrafted into lethally irradiated B6.SJL recipient
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mice. Reconstitutions were monitored by bleeding the recipient mice every four
weeks and analyzing the frequency of CD45.2 cells, which were derived from B6
or Alox15 BM cells, amongst the total CD45+ population (Figure 17). At all timepoints post-reconstitution, the contribution of Alox15-derived total CD45+ cells, T
cells, B cells and granulocytes were dramatically reduced compared to the
contribution of B6 donor-derived cells (Figure 18A). After 16 weeks, BM was
isolated and analyzed for progenitor subsets. Alox15 HSC were at a profound
disadvantage compared to B6-derived HSC under competitive conditions as
evidenced by a marked reduction in the proportion of Alox15-derived HSC
compared to B6-derived HSC in recipient mice (Figure 18B). In addition to the
HSC compartment, we also examined the contribution of B6 and Alox15 cells to
B, T and myeloid cell development by gating on CD45.2. In addition to the defect
in HSC, Alox15-derived cells exhibited additional defects at later stages of
differentiation similar to those described in Chapter 1 (Figure 19). There was a
further bias toward competitor-derived cells within B cell and T cell compartments
compared to Alox15-derived HSC (Figure 19A-B). Moreover, the defect in more
mature Alox15-derived cells was evident as early as four weeks following
reconstitution in the blood, when cells were derived from more differentiated
progenitors rather than the HSC (Figure 18A).
Additional competitive reconstitution assays using B6 and Alox15 BM
mixed 1:1 with congenic competitor cells demonstrated that limiting numbers of
Alox15 BM resulted in a further decrease in Alox15-derived HSC during
competitive reconstitution assays (Figure 20).
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We also performed competitive reconstitution assays with Alox15 heterozygous
cells. Similar to the lack of blood cell defects in Alox15 heterozygous mice
(Chapter 1), HSCs from Alox15 heterozygous mice were not defective during
competitive reconstitution assays compared to wild-type (Figure 21). Importantly,
however, Alox15 HSCs were defective compared to Alox15 heterozygous HSC
(Figure 21).
Defect in Alox15 HSC is primary
Multiple hematopoietic defects are present in Alox15 mice as described in
Chapter 1, including lymphocytes, monocytes and RBCs. Rather than a primary
defect in HSCs, it is possible that the reduced function of Alox15 HSCs is caused
by their need to continually replenish the more mature hematopoietic
compartments. Nonetheless, as the competitor cells provided a virtually normal
hematopoietic compartment during competitive reconstitution assays, these data
indicate that the defect in Alox15 HSCs was primary rather than secondary to
abnormalities in hematopoietic cells at later stages of differentiation. However, to
formally exclude the possibility that the defect in Alox15 HSCs was secondary to
later hematopoietic defects, we repeated the competitive reconstitution assays
with E14.5 fetal liver cells. Importantly, we found that Alox15 E14.5 fetal livers
were similar to B6 based on H&E staining and by flow cytometric analysis of
hematopoietic subsets and exhibited no overt phenotype (Figure 22A-B). In the
competitive reconstitution assays, B6 and Alox15 fetal liver cells were mixed 2:1
with normal congenic bone marrow to ensure readout of fetal liver-derived HSC
function in the context of a normal hematopoietic compartment. Even under
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these conditions, the contribution of Alox15-derived cells to the blood cell
populations was significantly reduced compared to B6 at all times post-transfer
into lethally irradiated congenic recipient mice (Figure 22C). Moreover, Alox15derived LSK and CD34-Flt3-LSK cells in the BM were significantly reduced
compared to wild-type (Figure 22D). These experiments were also conducted
with fetal liver cells mixed 1:1 with wild-type congenic competitive BM cells with
similar results (Figure 23). These data effectively demonstrate that the defect in
Alox15 HSCs is not secondary to defects in mature hematopoietic subsets.
Rather, 12/15-LOX directly regulates HSC function.
12/15-LOX regulates numbers, proliferation and function of LT-HSC
We further compared the distribution of HSCs within the LSK population of
B6 and Alox15 mice (Wilson et al., 2007; Wilson et al., 2008). Interestingly,
Alox15 BM had a decreased percentage of primitive dormant LT-HSC (CD34CD150+CD48-Flt3-LSK) and an increased percentage of more differentiated
MPP1 (CD34+CD150+ CD48+Flt3-LSK) compared to B6 (Figure 24A). The LTHSC population is highly enriched for HSC function and quiescent cells while the
more differentiated cells are highly proliferative and have decreased capacity to
self-renew. These data suggest that 12/15-LOX regulates the most primitive LTHSCs.
To determine whether the defect in Alox15 HSCs in the BM competitive
reconstitution assays was due to 12/15-LOX regulation of the absolute number of
LT-HSCs or the function of LT-HSCs, we performed competitive reconstitution
assays using equal numbers of purified LT-HSCs. Five hundred CD34-Flt374
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LSK cells, purified by cell sorting from B6 or Alox15 BM, were mixed with wildtype congenic competitor BM cells and injected into lethally irradiated recipient
mice. At all times post-reconstitution, there was a significant decrease in the
percentage of Alox15-derived blood cells (Figure 24B). Analysis of BM at 12
weeks post-reconstitution showed a decrease in the percentage and absolute
number of Alox15-derived LSK and CD34-Flt3-LSK compared to B6 (Figure 24C).
These data demonstrate that 12/15-LOX regulates the function of LT-HSC.
To determine the mechanism whereby 12/15-LOX regulates LT-HSC, we
compared the rates of cell death and proliferation in Alox15 and B6 HSC. B6 and
Alox15 LSK exhibited comparable levels of cell death ex vivo using both TUNEL
and AnnexinV/DAPI staining (Figure 25A-B). In addition, B6 and Alox15 LSK
exhibited similar cell death after sorting and in vitro culture with limiting levels of
cytokines (Figure 25C). Thus, 12/15-LOX does not regulate apoptosis of HSC.
However, Alox15 LSK contained an increased percentage of cycling cells
compared to wild-type (Figure 26A). This difference was most dramatic in the
CD34-LSK subset in which there was a decrease in the percentage of Alox15
cells in G0 (31.9% vs. 59.7%) but increased percentage of cells in G1 (38.5% vs.
17.3%) and SG2M (24.0% vs. 11.6%) (Figure 26B). Thus, 12/15-LOX regulates
the number, proliferation and function of primitive LT-HSCs. As LT-HSCs
proliferate, they may differentiate rather than self-renew leading to depletion of
the LT-HSC population. To formally test this hypothesis, we next tested whether
12/15-LOX regulates self-renewal.
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Defective self-renewal in Alox15 HSC
We tested whether 12/15-LOX regulates self-renewal capacity using two
approaches. In the first, we compared the self-renewal capacity of Alox15 and B6
HSCs in serial transfer assays in the absence of competitors. B6 and Alox15 BM
were transplanted into lethally irradiated mice. After 16 weeks, the bone marrow
was isolated and transplanted into a second lethally irradiated recipient (Figure
27A). Alox15 BM was able to reconstitute lethally irradiated primary recipient
mice but recapitulated the defects in Alox15 mice described above, compared to
the hematopoietic profile of primary recipients of B6 BM (Figure 14). However,
when BM cells from primary recipients were serially transferred, there was a
marked reduction in the survival of secondary recipients of Alox15 BM compared
to B6 (Figure 27B). The morbidity was not due to development of MPD because
the secondary recipients had comparable levels of neutrophils (Figure 27C).
These data demonstrate that Alox15 HSCs have a decreased capacity to selfrenew compared to wild-type HSC.
In the second approach we compared functionality of B6 and Alox15 HSCs
following treatment with 5-FU (200 mg/kg, i.p.), which depletes the mature
hematopoietic department resulting in division of HSCs. During competitive
reconstitutions, HSCs must be able to home to a bone marrow environment that
is altered after irradiation. The 5-FU approach has an advantage because it tests
the ability of HSCs to self-renew in their native niches. HSC self-renewal capacity
was assessed by determining the ratios of LSK to myeloid progenitors (MP) and
CLPs at day 4 post-injection, when the HSC are expected to be cycling in
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order to replenish the hematopoietic compartment. If the ratios of CLP/LSK or
MP/LSK are increased in 5-FU treated Alox15 BM compared to 5-FU treated
wild-type controls, it would indicate a preference for Alox15 HSCs to differentiate
rather than to self-renew while a reduced ratio indicates a preference for Alox15
HSCs to self-renew rather than differentiate (Figure 28). On day 4 post-5-FU
treatment, Alox15 BM contained a greater percentage of differentiated cells
compared to wild-type including an increase in the percentage of MP and
increased percentage and numbers of CLPs (Figure 29A-C). Moreover, the ratios
of MP/LSK, and CLP/LSK were increased compared to wild-type, demonstrating
a decreased capacity for Alox15 HSC to self-renew and an asymmetric division
skewed toward differentiation (Figure 29A). B6 and Alox15 LSK displayed similar
resistance to 5-FU per se because at day 2 post-5-FU treatment, there were no
differences in the numbers or percentages of LSK, MP or CLP. Furthermore, by
day 8 post 5-FU treatment, the LSK subset in B6 had expanded while Alox15
exhibited a marked reduction in number and percentage of LSK. (Figure 29B-C).
The reduction in LSK in BM of 5-FU-treated Alox15 mice on day 8 may be due to
exhaustion of the capacity of HSC to self-renew as required to maintain the
populations of LSK and progenitors. 5-FU-treated Alox15 mice also exhibited
decreased survival; 87.5% (7/8) of Alox15 mice succumbed to treatment
compared to 12.5% (1/8) for B6 mice (Figure 29D). The cause of death of the 5FU-treated Alox15 mice appeared to be severe anemia, as the HCT at day 8
post-treatment was 14.52% + 4.81% for Alox15 mice versus 32.53% + 8.08% for
B6 mice. The findings of increased proliferation but decreased numbers of
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LT-HSC in Alox15 mice, decreased survival of recipients that received serially
transferred Alox15 bone marrow and the increased ratios of Alox15
progenitor/LSK during 5-FU assays, when taken together, effectively
demonstrate that 12/15-LOX regulates HSC self-renewal.
Defective self-renewal of Alox15 HSC is associated with reduction 12/15-LOXdependent generation of lipid mediators and ROS
In order to determine which products of 12/15-LOX activity mediate HSC
function, we compared levels of ROS and lipid metabolites in B6 and Alox15
progenitors. Purified Alox15 LSK isolated by cell sorting exhibited increased
basal ROS levels ex vivo using the oxygen-sensitive CM-H2DCFDA probe
compared to B6 (Figure 30A). Because ROS levels are known to be decreased
in LT-HSC, the increase in basal ROS levels is likely a reflection of the
decreased numbers of LT-HSC within the Alox15 LSK (Figure 24) (Jang and
Sharkis, 2007). Interestingly, however, wild-type LSK exhibited a greater fold
increase in ROS compared to Alox15 after loading with exogenous AA indicating
that 12/15-LOX-mediated ROS production is in fact defective in Alox15 LSK
(Figure 30B). Hence, we speculate that 12/15-LOX-mediated ROS production
may contribute to 12/15-LOX signaling in HSCs. However, in the HSC it is
difficult to restore 12/15-LOX dependent ROS without affecting basal ROS, which
is increased due to other oxidases such as other enzymes involved in lipid
metabolism, NADPH-oxidases and mitochondria. In the future, it would be
interesting to elucidate the effects of these other oxidases in Alox15 HSC that
may contribute to the increased basal ROS levels and may also effect HSC
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function. In Chapter 3, we will elucidate that one effect of 12/15-LOX-generated
ROS is to regulate ICSBP/IRF-8 transcription factor nuclear accumulation
through redox-dependent signaling.
We also compared the generation of 12/15-LOX-mediated lipid
metabolites between B6 and Alox15 BM and progenitors. B6 and Alox15 BM or
Lin- cells enriched by column purification were loaded with 10 µM AA and lipid
products were detected using mass spectroscopy (Figure 31A). Alox15 BM
exhibited decreased 12(S)-HETE and 15(S)-HETE production while Alox15 Lincells produced less 12(S)-HETE and 13(S)-HODE compared to B6 (Figure 31B).
These differences were specific for 12/15-LOX products as there were no
differences in the 5-LOX product 5(S)-HETE. Interestingly, Alox15 BM also
exhibited decreased levels of the novel recently described 15(S)-HETE derivative
15-oxo-ETE, reported to inhibit proliferation in HUVEC cells (Wei et al., 2009).
We speculate that 12/15-LOX lipid product signaling by 12(S)-HETE and 13(S)HODE may mediate the effects of 12/15-LOX on HSC function.
As described in the introduction, 12/15-LOX produces multiple products
found in both the cell membrane, in the cytoplasm and released outside the cell.
The mass spectroscopy assay used only measures specific lipid products that
are released into the supernatant and it is likely that other 12/15-LOX-generated
products not measurable by our assay play a role in cell signaling that regulates
HSC function. Moreover, products of 12/15-LOX often act in combination, which
makes testing a single 12/15-LOX in isolation difficult to interpret. Product rediversion in the absence of 12/15-LOX occurs and another product of
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different AA-metabolizing enzyme such as 5-LOX may in fact regulate HSC
function. Lastly, lipid metabolites are very short-lived and stable derivatives of the
12/15-LOX products may be needed to test their ability to regulate HSC function.
Despite these challenges, we tested the ability of 12/15-LOX products,
12(S)-HETE and 15(S)-HETE, to alter HSC proliferation in vitro. BM cells from
Alox15 mice were isolated and treated with 12(S)-HETE and 15(S)-HETE in
varying concentrations for 30 minutes or overnight prior to cell cycle analysis.
Both 12(S)-HETE and 15(S)-HETE increased the percentage of cells in G0 and
decreased the percentage of cycling cells in the total BM population (Figure
32A). These effects were not dose-dependent and occurred at the lowest dose of
1 µM for both 12(S)-HETE and 15(S)-HETE. However, neither 12(S)-HETE nor
15(S)-HETE alone had any effect on the proliferation of LSK cells (Figure 32BC). Therefore, 12(S)-HETE nor 15(S)-HETE in isolation regulates HSC
proliferation, rather 12/15-LOX likely regulates HSC with greater complexity.
Products of 12/15-LOX may also regulate mature cells differently than LSK, as
12(S)-HETE and 15(S)-HETE both effected the proliferation of the total BM
population but not the LSK cells. Moreover, to regulate their cell division in vivo
HSC rely on signals provided by their niche, which is absent from this in vitro
assay.
12/15-LOX regulates ICSBP/IRF-8 nuclear accumulation and consequently
canonical Wnt signaling in hematopoietic progenitors
We previously reported that 12/15-LOX regulates ICSBP/IRF-8 nuclear
accumulation in peritoneal macrophages and Mac1+Gr1+ splenocytes
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(Middleton et al., 2006a; Middleton et al., 2006b). ICSBP/IRF-8 is also reduced in
aging stem cells and its targets, including Dab2, are involved in signaling
pathways implicated in HSC function (Hocevar et al., 2003; Stirewalt et al.,
2008). Therefore, we investigated whether 12/15-LOX regulates ICSBP/IRF-8 in
hematopoietic progenitors. ICSBP/IRF-8 protein in nuclear extracts of B6 and
Alox15 Lin-cKit+ cells enriched by column purification was quantified by
immunoblot ex vivo. The levels of nuclear ICSBP/IRF-8 protein were decreased
in Alox15 progenitors compared to B6 (Figure 33A) due to dysregulation at a
post-translational level as levels of ICSBP/IRF-8 total protein (MPER lysates) and
mRNA were not statistically different (Figure 33B-C).
To determine whether the decrease in ICSBP/IRF-8 nuclear accumulation
affected the expression of ICSBP/IRF-8 target genes in HSC, we analyzed
mRNA levels of known ICSBP/IRF-8-regulated genes using Q-PCR in B6 and
Alox15 LSK enriched by sorting. ICSBP/IRF-8 is known to negatively regulate
Dab2 and positively regulate Nf-1, Blimp1 and p15INK4b (Rosenbauer et al.,
2002; Schmidt et al., 2004; Zhu et al., 2004). Consistent with this, Dab2 mRNA
was increased while Nf-1, Blimp1 and p15INK4b mRNA were decreased in
Alox15 compared to wild-type LSK (Figure 33D).
We also analyzed expression of other genes that regulate HSC function not
believed to be directly regulated by ICSBP/IRF-8 including Hes1, Bmi, Hoxb4
and Gfi-1. Of these genes, only Hes1 was significantly decreased in Alox15
compared to wild-type LSK (Figure 33D). Because Hes1 is also decreased when
canonical Wnt signaling is inhibited (Fleming et al., 2008) and because the
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ICSBP/IRF-8 target Dab2 negatively regulates canonical Wnt signaling by
inhibiting disheveled and stabilizing axin (Hocevar et al., 2003; Jiang et al.,
2008), we investigated whether 12/15-LOX regulates canonical Wnt signaling.
We first determined that Dab2 protein was increased in Alox15 Lin-cKit+ cells
(Figure 34A). Because increased Dab2 leads to degradation of downstream
mediators of canonical Wnt signaling including β-catenin, we measured β-catenin
levels in wild-type and Alox15 progenitors. Indeed, β-catenin protein was
decreased in total lysates of Alox15 Lin-cKit+ progenitors compared to wild-type
(Figure 34B). These data implicate 12/15-LOX as a novel regulator of canonical
Wnt signaling. Canonical Wnt signaling is known to regulate HSC quiescence
and self-renewal (Fleming et al., 2008; Luis et al., 2009; Zhao et al., 2007) and
therefore the dysregulation of the Wnt signaling pathway including β-catenin,
may be at least one important mechanism underlying the reduced quiescence
and self-renewal capacity in Alox15 HSC.
The PI3-K pathway is another signaling pathway implicated in HSC
function. We have previously shown that phosphorylated Akt, which is
downstream of PI3-K was increased in developing Alox15 BM and that PI3-K
regulated nuclear accumulation of ICSBP/IRF-8 in Alox15 splenocytes(Middleton
et al., 2006b). Moreover, mice with activated PI3-K due to deletion of PTEN
exhibited HSC defects including loss of quiescence and developed leukemia.
These effects were mediated downstream by mammalian target of rapamycin
(mTOR) signaling. Treatment of these mice with the mTOR inhibitor rapamycin
reduced proliferation of PTEN-deficient HSC (Yilmaz et al., 2006). Therefore,
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we speculated that activated PI3-K signaling, specifically mTOR, may regulate
the defective HSC function in Alox15 mice. We tested whether treatment with
rapamycin reduced HSC proliferation in Alox15 mice. Treatment of Alox15 mice
with rapamycin for seven days decreased the proliferation amongst the total
Alox15 BM population (Figure 35A) demonstrating that the biological activity of
rapamycin and that the enhanced proliferation in mature Alox15 cells may be due
in part to mTOR signaling. On the other hand, Alox15 LSK displayed no
difference in proliferation in the presence of rapamycin (Figure 35B). Therefore,
the increased proliferation in Alox15 LSK is not due to the PI3-K-AKT-mTOR
pathway.
In order to directly address whether β-catenin regulates HSC function in
Alox15 mice, we attempted to introduce a murine stem cell retrovirus (MigR)
containing non-degradable β-catenin into Alox15 BM. However, retroviral
transduction of Alox15 cells was challenging. Treatment of Alox15 mice with 5FU caused depletion of the LSK and progenitors (Figure 29). Therefore, we
tested the feasibility of retroviral transduction of fetal liver cells, which do not
need treatment with 5-FU. Alox15 fetal liver cells were retrovirally transduced at
high levels initially. However, lethally irradiated recipients that received Alox15
retrovirally tranduced cells exhibited low survival rates, while all of the recipients
of B6 retrovirally transduced cells survived (Figure 36A). The few surviving
recipients of Alox15-tranduced cells exhibited low levels of GFP+ Mig retrovirus
(A) while the B6 retrovirally transduced cells were present at high numbers
(Figure 36A). Furthermore, surviving recipients of Alox15 transduced cells
95

96

97

but not recipients of B6 retrovirally tranduced cells, exhibited an expansion of
rare host cells (Figure 36B). Thus, it appears that Alox15 cells exhibit greater
sensitivity to retroviral transduction and do not survive/expand after transfer into
irradiated recipients. Lowering the dose of irradiation to the host or the addition of
competitor B6.SJL cells improved survival of recipients but did not improve
recovery of Alox15 retrovirally tranduced cells. The retroviral reconstitution in
Alox15 HSCs needs to be further optimized in future studies to directly address
the pathway whereby 12/15-LOX regulates HSC.
Implications
These studies establish the importance of unsaturated fatty acid
metabolism in hematopoiesis by demonstrating that Alox15 mice have a cellautonomous defect in hematopoietic development. Depletion of 12/15-LOX
results in a primary defect in HSC function. 12/15-LOX directly regulates the
number, proliferation and function of LT-HSCs. Furthermore, Alox15 HSCs
exhibit a decreased capacity to self-renew. The defects in Alox15 HSCs are
associated with a selective decrease in 12/15-LOX-mediated ROS and lipid
metabolites and are at least partly due to dysregulation of the transcription factor
ICSBP/IRF-8 and its downstream targets and to disruption of canonical Wnt
signaling.
Because Alox15 HSCs exhibit decreased quiescence, the striking
phenotype observed during the 5-FU assays at day 4 may be partially due to
increased sensitivity of Alox15 LSK to 5-FU. However, the sensitivity of 5-FU at
day 2 is similar between B6 and Alox15 LSK, suggesting that 5-FU is not
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acting directly on Alox15 LSK. Moreover, the increased numbers of Alox15 CLP
at day 4 compared to B6 demonstrate that Alox15 LSK are skewed in favor of
differentiation rather than self-renewal. The increased ratio of progenitors
compared to LSK at day 4, support the possibility that the exhaustion in the LSK
population is at least partly due to a decrease in self-renewal. The conclusion
that 12/15-LOX regulates self-renewal is also supported by the defect of Alox15
BM cells during serial reconstitution assays and by depletion of the LT-HSC
population in Alox15 BM.
ROS, which are functional by-products of 12/15-LOX activity (Conrad,
1999), are known to regulate HSC function. Because LT-HSCs exhibit decreased
ROS (Jang and Sharkis, 2007), the finding that Alox15 LSK exhibit increased
basal levels of ROS is likely a reflection of the reduction in LT-HSCs amongst
Alox15 LSK. Furthermore, basal ROS levels in HSCs may be determined by
other oxidases, such as NADPH-oxidase (Piccoli et al., 2007). In any case,
increased levels of ROS may contribute to the defect in HSC function and selfrenewal (Ito et al., 2006; Miyamoto et al., 2007; Tothova et al., 2007; Jang and
Sharkis, 2007). Moreover, ROS are known to regulate cell cycle progression
(Iiyama et al., 2006) and hence may in fact contribute to the increased cycling in
Alox15 LSK. However, we have demonstrated that 12/15-LOX-mediated ROS
production is defective in Alox15 LSK and hence may contribute to 12/15-LOX
signaling in HSCs.
Deficiency in 12/15-LOX also resulted in a marked reduction in the
generation of select 12/15-LOX lipid mediators by hematopoietic progenitors.
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12(S)-HETE and 13(S)-HODE were decreased while similar levels of 15(S)HETE and the 5-LOX product 5(S)-HETE were produced by Alox15 compared to
B6 progenitors. On the other hand, in Alox15 total BM cells there were decreased
12(S)-HETE and 15(S)-HETE but similar levels of 13(S)-HODE. The differences
in product formation between BM cells and the enriched progenitors are likely
due to the preference of murine 12/15-LOX to synthesize 12(S)-HETE rather
than 15(S)-HETE and differences in substrate (AA vs linoelic acid) availability.
Lipid metabolites of 12/15-LOX may regulate HSC function intrinsically
either individually or in combination and may act on multiple signal transduction
pathways including activation of protein kinase C by 12(S)-HETE, and MAPK by
13(S)-HODE (Conrad, 1999). Some 12/15-LOX products function by
incorporation into cell membranes, which can alter phosphoinositol (Girton et al.,
1994) and receptor signaling (Takata et al., 1994). Moreover, 12/15-LOX
products directly influence gene transcription by binding and activating
transcription factors such as PPAR-γ (Huang et al., 1999). Recent studies have
shown that the recently described 15(S)-HETE derivative 15-oxo-HETE inhibits
HUVEC proliferation (Wei et al., 2009). Further studies are required to determine
how 12/15-LOX lipid products regulate HSC proliferation and function.
Interestingly, fatty acid metabolism mediated by other enzymes that also
target AA as their substrate have been implicated in normal and leukemic HSC
function. The cyclooxygenase product prostaglandin E2 is known to signal
extrinsically through its receptor on HSC to promote self-renewal by enhancing
canonical Wnt signaling and β-catenin accumulation (North et al., 2007)
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(Goessling et al., 2009). Prostaglandin E2 has also been shown to regulate HSC
progression into cell cycle (Hoggatt et al., 2009). In addition, it was recently
reported that 5-lipoxygenase-deficient mice are protected from BCR-ABLinduced CML through inhibition of leukemic stem cell differentiation. In this study,
we demonstrate a seemingly opposing role for 12/15-LOX since 12/15-LOX
promotes self-renewal of normal HSC and suppresses development of myeloid
leukemia (Middleton et al., 2006b). Because cyclooxygenase, 5-LOX and 12/15LOX share AA as a substrate, it will be interesting in the future to investigate
whether substrate availability or substrate rediversion may contribute to the
phenotypes observed in the HSC compartment in the absence of 12/15-LOX or
5-LOX.
We have demonstrated that 12/15-LOX regulates nuclear ICSBP
accumulation in HSC. Intriguingly, ICSBP/IRF-8 has been proposed to play a role
in HSC function as aging wild-type murine and human HSC have decreased
levels of ICSBP/IRF-8 (Stirewalt et al., 2008). PU.1, a transcription factor that
interacts with ICSBP/IRF-8 is required for the capacity of HSC to self-renew
(Iwasaki et al., 2005). Both ICSBP/IRF-8 and PU.1 bind to the Dab2 promoter
and ICSBP/IRF-8 inhibits Dab2 expression (Rosenbauer et al., 2002) (Figure 37).
Dab2 functions as a negative regulator of canonical Wnt signaling by inhibiting
dishevelled-3 and by stabilizing axin leading to degradation of mediators of
canonical Wnt signaling including β-catenin (Hocevar et al., 2003; Jiang et al.,
2008; Figure 34; Figure 37). Axin over-expression has been shown to negatively
regulate HSC self-renewal (Reya et al., 2003). Other mediators of canonical
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Wnt signaling including β-catenin have also been shown to regulate self-renewal,
quiescence and function of HSCs (Nemeth et al., 2006; Zhao et al., 2007;
Fleming et al., 2008; Luis et al., 2009). Consistent with these data, Dab2 gene
and protein expression were amplified in Alox15 HSCs (Figure 37). Dab2
promotes β-catenin degradation leading to a decrease of β-catenin in Alox15
progenitors (Figure 37). The data presented indicate that 12/15-LOX may act
upstream of ICSBP/IRF-8 to promote Wnt signaling and hence self-renewal by
inhibiting transcription of Dab2. Therefore, 12/15-LOX is a novel regulator of
canonical Wnt signaling.
HSC function and hematopoietic differentiation are related and disruptions
in HSC function can lead to the development of leukemia; for example, in the
floxed PTEN mouse (Yilmaz et al., 2006). Alox15 mice develop a chronic
myelogenous leukemia-like MPD in 15% of the mice over the course of a year. It
is possible that the disruption in HSC function contributes to the development of
MPD in Alox15 mice (Middleton et al., 2006b). Dysregulation of ICSBP/IRF-8 and
decreased 12/15-LOX activity, particularly levels of 12(S)-HETE, are also
associated with human CML (Stenke et al., 1991; Takayama et al., 1983). The
contribution of decreased lipid mediators to the leukemic state remains largely
unknown, although eicosanoid products may induce apoptosis of myeloid
leukemic cell lines (Li et al., 2005; Mahipal et al., 2007). Because of the
development of a myeloid leukemia in Alox15 mice, we hypothesized that 12/15LOX also regulates myelopoiesis which we will address in Chapter 3.
In summary, we have found that 12/15-LOX-mediated fatty acid
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metabolism regulates the asymmetric division of HSCs by promoting quiescence
and self-renewal of LT-HSC. In the absence of 12/15-LOX, HSCs exhibit
increased proliferation and a bias in their asymmetric division toward
differentiation rather than self-renewal. Furthermore, we show that depletion of
12/15-LOX products is associated with a defect in nuclear accumulation of
ICSBP/IRF-8 and subsequent canonical Wnt signaling. Furthermore, I define
12/15-LOX as a novel regulator of canonical Wnt signaling. The data in this
chapter demonstrate that signaling downstream of fatty acid metabolism is an
important mechanism whereby HSC function is mediated. Further understanding
of these mechanisms may have implications for hematopoiesis, leukemia and
hematopoietic aging.
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CHAPTER 3: IRF-8-driven monopoiesis is dependent upon 12/15lipoxygenase mediated redox signaling
Myelopoiesis is the process whereby myeloid cells, granulocytes and
monocytes, are generated from HSCs. Hematopoietic differentiation from HSC
gives rise to cells that are progressively more restricted in their potential fate as
they commit to various lineages. For example, HSCs differentiate into MPP that
propagate both myeloid and lymphoid cells (Wilson et al., 2007). Further
differentiation of MPPs leads to the generation of CMP that can only sustain
erythropoiesis by differentiating into MEP and myelopoiesis by differentiating into
GMP, which in turn differentiate into either granulocytes or monocytes (Akashi et
al., 2000). Although phenotypic profiles can be used to distinguish hematopoietic
progenitors at various stages of differentiation, hematopoiesis occurs along a
continuum so that phenotypically defined progenitor populations can exhibit
heterogeneity with regard to their ability to commit and differentiate to alternative
lineages.
During myelopoiesis, IRF-8 functions in conjunction with PU.1 to activate
gene transcription that promotes monocytic differentiation while inhibiting gene
transcription that promotes granulocytic differentiation (Tamura et al., 2000).
Loss of IRF-8 transcriptional activity results in defects in monocytic development
and enhanced granulocytic differentiation (Scheller et al., 1999; Tsujimura et al.,
2002). Transcriptional activity of IRF-8 is dependent on its translocation to the
nucleus from the cytoplasm and our lab previously showed that IRF-8 nuclear
accumulation requires 12/15-lipoxygenase (12/15-LOX)-mediated signaling
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(Middleton et al., 2006a; Middleton et al., 2006b). However, the mechanism
whereby 12/15-LOX promotes nuclear accumulation of IRF-8 has not been
elucidated. In this chapter, I present evidence which demonstrates that 12/15LOX regulates ICSBP/IRF-8 by redox signaling and implicates SHP-2 as a redox
sensitive factor.
Although much is known about the transcription factors that regulate
myeloid cell specification, less is understood about the upstream signaling
pathways required for these cell fate decisions. In this chapter, I present data
which demonstrate that myelopoiesis is regulated by a novel 12/15-LOXdependent signaling pathway. Little was previously known of the consequences
of 12/15-LOX signaling during myelopoiesis. Although others reported that
addition of 12(S)-HETE and 15(S)-HETE to human CD34+ progenitors decreased
the numbers of granulocyte-macrophage colonies in methylcellulose assays
(Desplat et al., 2000), the role of 12/15-LOX in regulation of granulocytic and
monocytic lineage specification remained to be determined.
ROS generated as byproducts of 12/15-LOX-mediated lipid metabolism
also function as second messengers by regulating cellular redox signaling. For
instance, ROS generated by lipoxygenases can oxidatively modify proteins such
as SHP-2 resulting in their inactivation (Pani et al., 2000; Chen et al., 2009a).
Interestingly, SHP-2 negatively regulates ICSBP/IRF-8 transcriptional activity,
known to promote monocyte differentiation (Huang et al., 2006; Tsujimura et al.,
2002) and inhibition of SHP-2 results in decreased granulocyte differentiation
(Jack et al., 2009). However, a role for ROS per se has not been previously
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demonstrated in GMP or in the regulation of cell fate decisions.
Because monocyte numbers are reduced (Chapter 1) while the
percentage of granulocytes is increased in Alox15 mice (Middleton et al., 2006b),
I hypothesized that 12/15-LOX regulates myeloid cell fate decisions. In this
chapter, I present data that establish that Alox15 myeloid cell development is
skewed towards the granulocytic lineage at the expense of monopoiesis.
Furthermore, the data indicate that the bias in cell fate is due to 12/15-LOXdependent redox signaling that mediates nuclear accumulation of IRF-8 to drive
monopoiesis and inhibit granulopoiesis.
Alox15 progenitors exhibit enhanced granulopoiesis and decreased monopoiesis
We previously demonstrated that 12/15-LOX-deficient Alox15 mice had
reduced numbers of monocytes in the blood and increased percentage of
granulocytes in the blood, spleen and bone marrow (BM) (Kinder et al submitted;
(Middleton et al., 2006b). Therefore, we hypothesized that 12/15-LOX regulates
myelopoiesis. Using real time PCR analysis of enriched progenitor subsets, we
determined that 12/15-LOX was expressed at varying levels throughout
myelopoiesis (Figure 38) with the highest levels of 12/15-LOX expression in CMP
and MEP. Because these progenitors have erythroid potential, these data were
consistent with the fact that 12/15-LOX products were involved in erythroid
differentiation (Chapter 1; Kuhn and Brash, 1990; van Leyen et al., 1998).
However, 12/15-LOX was also expressed in HSC and GMP at levels similar to
Gr1+ splenocytes.
To test the hypothesis that 12/15-LOX regulates myelopoiesis, we
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plated cells from B6 and Alox15 mice in methylcellulose containing IL-6, IL-3,
stem cell factor (SCF) and erythropoietin (Epo) and compared the frequency of
colony-forming units-granulocyte (CFU-G) to that of colony-forming unitsmacrophage (CFU-M). BM cells from Alox15 mice generated an increased ratio
of CFU-G to CFU-M compared to BM cells from B6 mice (Figure 39A). BM cells
from Alox15 mice gave rise to an increased number of total colonies, due to an
increased number of CFU-G and CFU-granulocyte-macrophage (CFU-GM). In
contrast, Alox15 BM cells gave rise to a decreased number of CFU-M compared
to B6 (Figure 39A). Splenocytes from Alox15 mice had a trend towards increased
total number of colonies and also generated an increased ratio of CFU-G to
CFU-M. Like BM, splenocytes gave rise to an increased number of CFU-G and
CFU-GM (Figure 39B). These data demonstrate that 12/15-LOX indeed regulates
myelopoiesis and that absence of 12/15-LOX results in skewing of myelopoiesis
towards granulocytic development.
Similar to BM cells plated in methylcellulose in the presence of IL-3, IL-6,
Epo and SCF (Figure 40A), BM cells from Alox15 mice grown in the presence of
GM-CSF also were skewed towards granulocyte development as indicated by an
increased CFU-G/CFU-M ratio compared to B6 (Figure 40A). The skewing
towards granulocyte development in the presence of GM-CSF was a result of
increased numbers of Alox15 CFU-G colonies and hence enhanced
granulopoiesis compared to B6. Similarly, the numbers of CFU-GM were also
increased in Alox15 compared to B6 in the presence of GM-CSF (Figure 40A).
These data provide additional evidence for enhanced granulopoiesis by
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Alox15 cells.
The cytokines provided in the experiments described above, IL-3, IL-6,
SCF and Epo or GM-CSF, do not instruct lineage fate but rather support
development of multiple myeloid cell fates. In order to determine the effect of
instructive cytokines on the differentiation of B6 and Alox15 BM cells, we plated
B6 and Alox15 BM cells in methylcellulose in the presence of M-CSF or G-CSF
and quantified colony number and phenotype. Interestingly, cells from Alox15 BM
gave rise to an increased number of total colonies in the presence of both M-CSF
and G-CSF compared to cells from B6 BM. However, in the presence of M-CSF,
cells from Alox15 BM generated more CFU-GM, but not CFU-M. In contrast, in
the presence of G-CSF, cells from Alox15 BM gave rise to an increased number
of both CFU-GM and CFU-G compared to cells from B6 BM (Figure 40B). Taken
together, these data demonstrate that Alox15 BM cells exhibit an increased
frequency of CFU-GM and enhanced granulocytic differentiation.
The increased number of total myeloid colonies that developed in
methylcellulose assays with Alox15 cells suggested that there might be an
increased number of myeloid progenitors in Alox15 BM compared to B6.
Specifically, the increase in CFU-GM in the presence of all cytokines including MCSF, suggest that the GMP population is specifically increased in Alox15 mice.
Accumulation of defective GMP in Alox15 mice
To determine whether 12/15-LOX regulates the numbers of myeloid
progenitor populations such as GMP in unmanipulated mice, we employed
multicolor flow cytometric analysis to determine the percentage and numbers
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of phenotypic progenitor populations. At all ages tested, Alox15 mice had similar
percentages of Lin-Sca1+cKit+ cells (LSK, a population enriched for murine HSC),
CMP and MEP but an increased percentage of GMP in the BM compared to B6
(Figure 41A-C). Using manual counts of total bone marrow cells coupled with the
percentages of the progenitor populations determined by multicolor flow
cytometric analysis, we determined that absolute numbers of GMP were also
increased in Alox15 BM compared to B6 (Figure 41E). The increased percentage
of GMP was also evident in Alox15 spleen (Figure 41D).
There are several potential explanations for the increased number of GMP
progenitors in Alox15 mice. First, CMP may produce more GMP at the expense
of MEP. Although possible, this is not likely as there were similar numbers of
erythroid progenitors (BFU) produced from Alox15 BM in methylcellulose assays
(Figure 39A), and similar numbers of MEP in B6 and Alox15 mice (Figure 41).
Second, Alox15 GMP may expand by proliferating and/or through enhanced
survival. Alternatively, Alox15 GMP differentiation may be blocked resulting in
accumulation of GMP as they fail to progress from this differentiative stage.
To determine whether Alox15 GMP exhibit enhanced proliferation, we
performed cell cycle analysis of B6 and Alox15 GMP ex vivo using incorporation
of Hoechst dye, which determines DNA content. B6 and Alox15 GMP had
comparable percentages of cells in SG2M (Figure 42A). Moreover, cell survival
was similar between B6 and Alox15 GMP as measured by the percentage of
cells expressing AnnexinV, an apoptotic marker, ex vivo and after stimulation
with SCF in vitro (Figure 42B-C). Therefore, Alox15 GMP do not appear to
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be increased due to enhanced proliferation or decreased apoptosis.
To test the hypothesis that GMP accumulate in Alox15 mice due to a block
in differentiation, we isolated enriched populations of LSK, CMP and GMP from
BM of B6 and Alox15 mice by cell sorting and compared their capacity to
differentiate in methylcellulose assays. LSK and CMP from Alox15 mice both
generated increased numbers of CFU-G but decreased numbers of CFU-M
compared to B6 resulting in increased ratios of CFU-G/CFU-M compared to B6
(Figure 43A-B). These data recapitulated results of the methylcellulose assays
using whole BM cells.
On the other hand, GMP from Alox15 mice exhibited a defect in the
capacity to differentiate in methylcellulose assays. GMP from Alox15 mice
generated fewer total colonies, gave rise to significantly fewer M-CFU, and
exhibited subtle decreases in CFU-G and CFU-GM. In spite of the subtle
decrease in CFU-G, the ratio of CFU-G/CFU-M from Alox15 GMP was increased
compared to B6 as we observed for LSK and CMP (Figure 43C). Although these
data were consistent with a skewing towards granulocytic differentiation and
defective monocytic development, it was not clear whether the defect in Alox15
GMP was specific for monocytic development. To determine the specificity of
defective differentiation of Alox15 GMP, we compared differentiation of B6 and
Alox15 GMP in the presence of the instructive cytokines M-CSF or G-CSF in
methylcellulose assays. GMP from B6 and Alox15 mice produced similar
numbers of granulocytic colonies in response to G-CSF demonstrating that
Alox15 GMP did not exhibit defective differentiation nor cytokine
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hypersensitivity to G-CSF per se. However, GMP from Alox15 mice gave rise to
fewer monocytic colonies in response to M-CSF than GMP from B6 mice (Figure
43D).
These data illustrate that there is an accumulation of GMP in Alox15 mice
likely caused by a selective block in monocytic differentiation and decreased exit
from this progenitor stage. In the absence of 12/15-LOX, there is enhanced
granulocytic development at the expense of monopoiesis. Therefore, I conclude
that 12/15-LOX functions to promote monocytic development and inhibit
granulocytic development. (Figure 44).
Redox regulation of IRF-8 nuclear accumulation
We previously demonstrated that 12/15-LOX regulated IRF-8/ICSBP
nuclear accumulation in mature myeloid cells (Middleton et al., 2006a; Middleton
et al., 2006b) and in Lin-cKit+ immature myeloid progenitors (Chapter 2) (Kinder
et al submitted). Moreover, IRF-8/ICSBP is known to critically promote monocyte
differentiation and inhibit granulocyte development (Tamura et al., 2000;
Tsujimura et al., 2002; Scheller et al., 1999). Therefore, we hypothesized that
defective IRF-8/ICSBP transcriptional activity may cause the skewed
granulopoieis and defective monopoiesis in Alox15 mice. To test this hypothesis,
we analyzed IRF-8-regulated genes, NF-1 (Zhu et al., 2004) and Egr-1 (Tamura
et al., 2000), in CMP and GMP from B6 and Alox15 mice. CMP and GMP from
Alox15 mice expressed decreased levels of NF-1 and Egr-1 compared to B6
(Figure 45A) while the mRNA levels of genes important in myeloid differentiation
but not regulated by IRF-8, such as PU.1 and c/EPBα (Tamura et al., 2000),
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were comparable between B6 and Alox15 progenitor subsets (Figure 45A),
indicating a selective defect in IRF-8-mediated gene transcription. The defect in
IRF-8/ICSBP-mediated gene transcription was not due to decreased expression
of IRF-8/ICSBP as levels of IRF-8/ICSBP mRNA were similar between B6 and
Alox15 CMP and GMP (Figure 45A). These data are consistent with evidence
that 12/15-LOX can regulate IRF-8/ICSCP in a post-transcriptional manner
(Chapter 2) (Middleton et al., 2006b).
To determine how 12/15-LOX regulates IRF-8 transcriptional activity in
developing monocytes, we used B6 and Alox15 BMM, which recapitulated the
defect in NF-1 gene expression and expressed similar levels of IRF-8 in Alox15
CMP and GMP (Figure 45B). To determine which 12/15-LOX-products might
regulate IRF-8-mediated gene transcription, we compared levels of lipid
metabolites and ROS in B6 and Alox15 BMM. As expected, we found that Alox15
BMM were defective in production of the 12/15-LOX-generated lipid metabolite
12(S)-HETE and in basal levels of ROS compared to B6 (Figure 45C-D).
Moreover, Alox15 BMM produced increased levels of the 5-LOX product 5(S)HETE in response to AA suggesting substrate re-diversion into the 5-LOX
pathway (Figure 45C).
To determine the potential impact of the reduction in ROS on IRF-8
mediated gene transcription, we treated B6 BMM overnight with a ROS
scavenger, Tiron, which decreased levels of ROS (Figure 46A) and measured
transcription of the IRF-8 target gene NF-1. Conversely, we treated Alox15 BMM
with BSO, which increases ROS (Figure 46A) by inhibiting synthesis of the
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cellular anti-oxidant gluthathione. Interestingly, we found that NF-1 gene
expression was regulated in part by ROS levels. The ROS scavenger Tiron
decreased NF-1 expression in B6 BMM while the ROS inducer, BSO, restored
NF-1 transcription in Alox15 BMM (Figure 46B). To determine whether ROSsignaling alters NF-1 transcription by regulating the nuclear accumulation of IRF8, levels of IRF-8 were quantified in nuclear lysates of B6 BMM treated with Tiron
overnight. Both B6 BMM treated with Tiron and Alox15 BMM exhibited a
decrease in IRF-8 nuclear accumulation compared to untreated B6 BMM,
indicating that low ROS levels contribute to the decreased nuclear accumulation
of IRF-8 (Figure 46C). Conversely, elevation of ROS levels in Alox15 BMM by
the addition of BSO increased IRF-8 nuclear accumulation (Figure 46D). This
regulation was not due to alterations in IRF-8 gene expression, which was similar
between treated and untreated B6 and Alox15 BMM (Figure 46E). Moreover, the
nuclear levels of ICSBP/IRF-8 with the addition of BSO in Alox15 BMM were
restored to the levels observed in untreated B6 BMM, suggesting that redox
signaling is the primary mediator of 12/15-LOX-dependent activation of IRF-8
(Figure 46F). These data indicate that 12/15-LOX regulates IRF-8 nuclear
accumulation and subsequent gene transcription through ROS-mediated
signaling.
Redox regulation of monocyte development in Alox15 progenitors
If 12/15-LOX regulates nuclear IRF-8 accumulation through ROSmediated signaling and as IRF-8 promotes monocyte development, we expected
that increasing ROS-signaling should also restore monocytic differentiation in
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Alox15 progenitors. To determine the impact of redox signaling on Alox15
myeloid development, we plated BM cells from Alox15 mice in methylcellulose in
the presence or absence of BSO. Interestingly, the presence of BSO increased
Alox15 monocytic development (CFU-M) and decreased granulocyte
development (CFU-G) in methylcellulose resulting in a decreased ratio of CFUG/CFU-M (Figure 47A). Increasing ROS levels through the addition of BSO also
increased monocyte development from Alox15 GMP in methylcellulose assays.
GMP from Alox15 mice plated in the presence of BSO generated more CFU-M
colonies than in the absence of BSO. This resulted in a decreased ratio of CFUG/CFU-M in the presence of BSO (Figure 47B). Moreover, addition of BSO to B6
BM cells in methylcellulose had a slight trend towards increased CFU-M, though
this was not significant (Figure 48A). The levels of ROS in B6 may be optimal for
monocyte development and further increase of redox signaling may have a
negative effect on cell survival (Jones, 2008). Taken together, these data indicate
that 12/15-LOX regulates monocyte development through redox signaling and
restoration of redox signaling in Alox15 progenitors is sufficient to restore
monocyte development.
On the other hand, we also tested the effects of 12/15-LOX lipid products
on B6 and Alox15 myeloid cell development during methylcellulose assays.
12/15-LOX products had no effect on B6 differentiation. While 12(S)-HETE and
13(S)-HODE had no effect on Alox15 myeloid cell development, addition of
15(S)-HETE to methylcellulose decreased the ratio of CFU-G/CFU-M ratio by
Alox15 progenitors (Figure 48B). Others showed that 15(S)-HETE, but not
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13(S)-HODE, can modulate redox signaling downstream to mediate some of its
effects (Mahipal et al., 2007). Therefore, it is possible that 15(S)-HETE regulates
myeloid differentiation in Alox15 progenitors through redox signaling. It would be
an interesting future direction to discern the exact contribution of 15(S)-HETE
signaling to Alox15 myeloid cell differentiation. However, since 15(S)-HETE
levels were similar between B6 and Alox15 BMM and Lin- progenitors (Figures
45, 31), I concentrated on the role of 12/15-LOX-dependent ROS signaling which
was decreased both in Alox15 BMM and LSK. Moreover, 12(S)-HETE, which is
decreased in both Alox15 BMM and Lin- progenitors, had no effect on Alox15
myeloid cell differentiation (Figure 48B).
The data presented thus far demonstrate that ICSBP/IRF-8 is
transcriptionally active at relatively high levels of ROS. Therefore at higher levels
of ROS a redox modification of cysteine residue(s) in ICSBP/IRF-8 or an
upstream signal transducer promotes ICSBP/IRF-8 nuclear accumulation.
ICSBP/IRF-8 does contain cysteines in its protein sequence. However, it is likely
that modifications of these cysteine residues would inactivate rather than activate
its transcriptional activity similar to the action of phosphorylation on ICSBP/IRF-8
transcription of NF-1 (Huang et al., 2006). Moreover, most non-zinc finger
transcription factors such as HIF1α and NF-κB are regulated by redox signaling
by an upstream signal transducer that is the target for redox modifications
(Haddad, 2002a). Although I cannot formally exclude that ICSBP/IRF-8 was
directly regulated by oxidative modifications, I hypothesized that an upstream
regulator of ICSBP/IRF-8 was the target for redox modifications. Indeed,
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SHP-1 and SHP-2, which negatively regulate ICSBP/IRF-8 transcriptional activity
(Huang et al., 2006; Kautz et al., 2001), are known targets of redox modifications
(Chen et al., 2009a; Heneberg and Draber, 2005; Weibrecht et al., 2007).
Therefore, I hypothesized that ROS produced by 12/15-LOX may oxidize SHP1/2 leading to its functional inactivation. SHP-1/2 activity may be increased at low
levels of ROS, such as in Alox15 progenitors and BMM. Moreover, I
hypothesized that the higher activity of SHP-1/2 in Alox15 cells may inhibit
ICSBP/IRF-8 transcriptional activity leading to a block in monocyte development
and enhanced granulocyte development.
To test this hypothesis, we analyzed the effect a SHP1/2 inhibitor, NSC87877 would have on differentiation of Alox15 BM cells in methylcellulose
assays. Increasing concentrations of 10 µM and 50 µM NSC-87877 restored
monocyte development and decreased granulocyte development in
methylcellulose assays with Alox15 BM cells. Inhibition of SHP1/2 with 50 µM
NSC-87877 resulted in an increase in CFU-M and an accompanying decrease in
CFU-G (Figure 49A). However, this concentration of NSC-87877 (50 µM) was
recently shown to effect differentiation of wild-type BM cells in methylcellulose
assays (Jack et al., 2009). Importantly, we demonstrate that 10 µM of NSC87877 had no effect on B6 myeloid differentiation, but still decreased the ratio of
CFU-G/CFU-M generated by Alox15 BM cells (Figure 49B). Therefore,
dysregulation of SHP1/2 activity may contribute to the skewed granulocyte
differentiation of Alox15 progenitors.
Ideally, we would like to compare the activation of SHP-2 in B6 and
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Alox15 progenitors. Although I have attempted to measure phosphorylated
stimulation concentration, progenitor cells and kinetics. Moreover, although SHP2 in BMM, my conditions were not optimal. I need to further optimize cytokine
phosphorylation can increase the activity of SHP-2, it is not required (Lu et al.,
2001) and therefore may not be the best measure of its activity. A future direction
of these studies would be to measure oxidized SHP-2 in Alox15 progenitors.
These studies will also require further optimization, as there is no specific
antibody for oxidized SHP-2 and introduction of oxygen to the protein lysates
would eliminate differences.
12/15-LOX regulates IL-12p40 expression in a redox-dependent mechanism
The data presented thus far indicate that 12/15-LOX regulates ICSBP/IRF8 nuclear accumulation through redox signaling in Alox15 progenitors and
immature BMM. I hypothesized that this novel pathway may be a common
mechanism by which 12/15-LOX regulates ICSBP/IRF-8-dependent gene
expression. Our lab previously showed that 12/15-LOX regulates IL-12p40
expression through ICSBP/IRF-8 in mature macrophages (Middleton et al.,
2006a). Therefore, we tested whether 12/15-LOX also regulates ICSBP/IRF-8
transcriptional activity of IL-12p40 expression in mature macrophages through
redox signaling. We measured levels of IL-12p40 mRNA by real time PCR
analysis in thioglycollate-elicited macrophages from Alox15 mice in the presence
or absence of 10 µM BSO following stimulation with 1 µg/ml LPS and 500 U/ml
IFNγ for 4 hours. Addition of BSO restored IL-12p40 expression in Alox15
macrophages (Figure 50A) suggesting that 12/15-LOX regulates IL-12p40
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expression in Alox15 macrophages through redox signaling. These results are
consistent with the results in Dr. Middleton’s dissertation, in which she treated B6
thioglycollate-elicited macrophages with the ROS scavenger, Tiron, and found
decreased levels of ICSBP/IRF-8 nuclear accumulation and IL-12p40 expression.
We also tested whether SHP-1/2 regulates IL-12p40 expression in Alox15
macrophages. Addition of 100 µM NSC-87877 to Alox15 thioglycollate-elicited
macrophages also increased levels of IL-12p40 expression (Figure 50B).
Therefore, the mechanism by which 12/15-LOX regulates ICSBP/IRF-8
transcriptional activity in immature progenitors is conserved in the regulation of
IL-12p40 expression by mature macrophages.
Taken together, these data demonstrate that 12/15-LOX generated ROS
likely inhibits SHP1/2 activity. Inhibition of SHP1/2 appears to promote nuclear
accumulation of ICSBP/IRF-8 and thus modulates its transcriptional activity
resulting in monocyte development and inhibition of granulocyte development in
hematopoietic progenitors and IL-12p40 gene expression in macrophages
(Figure 51). In the absence of 12/15-LOX, ROS levels are decreased resulting in
increased SHP1/2 activity. As others reported, increased SHP1/2 activity leads to
de-phosphorylation of ICSBP/IRF-8 that inhibits its association with other
transcription factors such as PU.1 (Kautz et al., 2001) (Huang et al., 2006). This
dysregulation of ICSBP/IRF-8 results in decreased ICSBP/IRF-8 transcriptional
activity leading to enhanced granulocyte differentiation and decreased monocyte
differentiation by Alox15 myeloid progenitors and decreased IL-12p40 expression
in mature Alox15 macrophages (Figure 51).
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Implications
In this chapter, I present data that 12/15-LOX promotes monocyte
development through redox regulation of the transcription factor ICSBP/IRF-8.
Alox15 progenitors exhibit enhanced granulopoiesis at the expense of
monopoiesis. The excess accumulation of functional (CFU-GM) and phenotypic
GMP in Alox15 mice is accompanied by defective monocyte differentiation, which
is likely a result of decreased IRF-8-mediated gene transcription. We showed
that 12/15-LOX regulates IRF-8 nuclear accumulation downstream of redox
signaling possibly through oxidation of SHP-2. ICSBP/IRF-8 nuclear
accumulation and transcriptional activity subsequently promotes monocyte
differentiation and inhibits granulocyte differentiation in myeloid progenitors and
promotes IL-12p40 expression in mature macrophages (Figure 51).
Because NSC-87877 recognizes both SHP-1 and SHP-2, we cannot
discern from these experiments which mediator(s) regulate Alox15 myeloid
differentiation. The contribution of SHP-1 versus SHP-2 is also currently not
known in the case of normal differentiation of wild-type cells (Jack et al., 2009).
Although the role of constitutively active SHP-2 mutations has been well
documented in leukemia (Loh et al., 2004; Niihori et al., 2005; Schubbert et al.,
2005), the role of SHP-1 during leukemia and myeloid differentiation is less well
understood (Bruecher-Encke et al., 2001; Luo et al., 2004). However, both SHP1 and SHP-2 are regulated by redox modifications of their catalytic cysteine
residues (Chen et al., 2009a; Heneberg and Draber, 2005; Weibrecht et al.,
2007) and both can bind to ICSBP/IRF-8 (Huang et al., 2006; Kautz et al.,
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2001). A future direction would be to determine the impact on SHP-1 and SHP-2
on myeloid cell differentiation in B6 and Alox15 mice in order to further elucidate
the pathway by which 12/15-LOX regulates ICSBP/IRF-8 through redox
signaling. In addition, an ICSBP/IRF-8 reporter assay could further elucidate the
effect of redox signaling on ICSBP/IRF-8 transcriptional activity.
The increased numbers of GMP in Alox15 mice is likely due to an
accumulation as a result of defective differentiation. The accumulation of GMP
could reflect enhanced proliferation or survival, increased differentiation of CMP
to GMP, increased self-renewal or decreased ability of GMP to progress from this
differentiative stage. These possibilities are not mutually exclusive. For instance,
gfi-1 regulated the numbers of GMP progenitors through a Hox9A-dependent
mechanism that was distinct from the mechanism whereby it regulated terminal
granulocyte formation (Horman et al., 2009). In our study, we demonstrated that
GMP from B6 and Alox15 mice had similar rates of proliferation and survival
(Figure 42) eliminating the first possibility. B6 and Alox15 mice had similar
numbers of MEP (Figure 41) and similar numbers of BFU in methylcellulose
assays in which BM and LSK were plated (Figures 38, 41). Therefore, it is
unlikely that Alox15 CMP are differentiating to GMP at the expense of MEP. The
decreased BFU from spleen and CMP may be a result of the defective red blood
cell development rather than a decrease in the numbers of MEP as 12/15-LOX is
known to regulate red blood cell development (Kuhn and Brash, 1990; van Leyen
et al., 1998). Moreover, the absence of 12/15-LOX results in the inability of cells
to self-renew (Chapter 2) so it is unlikely that GMP from Alox15 mice were
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expanded due to self-renewal. Taken together, our results suggest that the
accumulation of GMP is largely due to a block in progression from this progenitor
stage as demonstrated by the defective differentiation of Alox15 GMP in
methylcellulose assays (Figure 43). However, we cannot formally exclude the
possibility that 12/15-LOX also regulates the size of progenitor populations and
monocyte differentiation through other distinct mechanisms.
BM cells, splenocytes, LSK and CMP from Alox15 mice gave rise to
increased numbers of granulocytes compared to B6. On the other hand, GMP
from Alox15 mice did not exhibit enhanced granulocyte differentiation during
methylcellulose assays. These data suggest that GMP in the methylcellulose
assays are relatively limited in their ability to differentiate to the granulocyte
lineage in the presence of IL-3, IL-6 and SCF and a proportion may already be
committed to the monocyte lineage. Indeed, GMP represent a stage along the
continuum of myeloid cell differentiation and are a heterogonous population. A
proportion of Alox15 GMP may already be committed to become monocytes.
However, the defect in monocyte differentiation of Alox15 GMP may result in cell
death rather than differentiation to the alternative granulocyte cell fate. Addition
of BSO rescues the survival and differentiation of Alox15 GMP committed to the
monocyte lineage. On the other hand, BM and spleen contain LSK and CMP,
which are more immature and may exhibit a greater capacity to differentiate to
the granulocytic lineage resulting in an increased number of Alox15 CFU-G in the
methylcellulose assays. Increasing ROS levels by the addition of BSO decreased
the number of CFU-G in methylcellulose assays with whole BM. In the
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absence of 12/15-LOX, there may be rediversion of monocyte lineage into the
granulocyte lineage. Indeed, signaling that promotes monocyte development
represses granulocyte development including by transcriptional activity of IRF-8
(Friedman, 2007; Tsujimura et al., 2002; Scheller et al., 1999; Tamura et al.,
2000). Moreover, when instructed to differentiate to granulocytes by G-CSF, B6
and Alox15 GMP have similar numbers of granulocytic colonies. Therefore,
Alox15 GMP are not hypersensitive to G-CSF and skewing of myelopoiesis
towards granulocyte differentiation in the presence of non-instructive cytokines
occurs as a result of defective monocyte differentiation.
The establishment of a redox-dependent mechanism for ICSBP/IRF-8
nuclear accumulation suggests the possibility that other mediators of redox
signaling may also regulate monocyte development. Though it was known that
increased levels of ROS promote monocyte to macrophage transition
(Yamamoto et al., 2009), our studies implicate an additional role for ROSsignaling at an earlier stage of monocytic differentiation. Our finding that
increasing ROS levels by the addition of BSO in Alox15 BM decreased
granulocyte development are in agreement with a previous study that
demonstrated ROS signaling, generated by dominant negative NF-κB, inhibited
granulocyte differentiation (Nakata et al., 2004). However, the previous study did
not examine the effects on mature monocyte development and the ROS
generated in the previous study were at levels that mediated apoptosis. Rather,
our studies were done at more physiological levels of ROS that did not cause
apoptosis. ROS-signaling at physiological levels is known to promote
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cytokine receptor signal transduction, including downstream of the cytokines Epo
and GM-CSF (Iiyama et al., 2006; Sattler et al., 1999). It is likely that increasing
ROS levels in Alox15 progenitors functions similarly to potentiate signal
transduction resulting in ICSBP/IRF-8 nuclear accumulation and transcriptional
activity and subsequent monocyte differentiation.
The increased levels of 5(S)-HETE in Alox15 BMM may reflect substrate
re-diversion into the 5-LOX pathway in the absence of 12/15-LOX (Figure 5C).
Interestingly, the 5-LOX pathway has been shown to promote granulocyte
development through the production of leukotreine D4 (Miller et al., 1990).
Moreover, inhibition of 5-LOX potentiated monocyte development (Stixova et al.,
2009). Although these studies were done on cell lines, they suggest that 5-LOX
and 12/15-LOX have opposing roles in myeloid cell fate decisions. A balance of
lipid mediator signaling may therefore be important for the regulation of myeloid
cell development.
Because leukemia can result from aberrant myeloid cell development,
elucidation of the processes that govern myelopoiesis may provide insight into
leukemogenesis. Indeed, a small percentage of Alox15 mice developed a
myeloid proliferative disease (MPD) over the course of a year, characterized by
an accumulation of granulocytes (Middleton et al., 2006b). Moreover, IRF-8deficient mice, which exhibited a block in monocyte development and enhanced
granulocyte development, developed a similar MPD (Holtschke et al., 1996). One
can speculate that a block in monocyte development coupled with a skewing
towards granulocyte development found in both Alox15 and IRF-8-deficient
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mice may cause a favorable scenario for the development of a granulocytic
leukemia. Indeed, an accumulation of GMP is also found during human chronic
myelogenous leukemia and is believed to be the target of a secondary oncogenic
event that drives the blast crisis phase of disease (Jamieson et al., 2004).
Redox regulation of IRF-8 nuclear accumulation and gene transcription
may also play an important role during inflammation. Our lab previously showed
that 12/15-LOX regulates IL-12p40 transcription in mature macrophages through
IRF-8 (Middleton et al., 2006a). In this chapter we demonstrate that 12/15-LOX
likely regulates IRF-8 nuclear accumulation and IL-12p40 gene transcription
through ROS signaling in peripheral inflammatory macrophages, similar to our
findings in immature BMM. Inflammation and inflammatory cytokines can induce
ROS production and in turn ROS-signaling contributes to further inflammation
and cytokine production (Haddad and Harb, 2005; Lambeth et al., 2008;
Shakibaei et al., 2005). Similarly, increased ROS levels during inflammation may
inhibit SHP1/2 leading to activation IRF-8 nuclear accumulation and
transcriptional activity of inflammatory cytokines in mature macrophages.
In summary, we demonstrate that ROS-signaling regulates IRF-8 nuclear
accumulation and subsequent monocyte differentiation in Alox15 mice. This
results in an accumulation of defective GMP and a skewing towards
granulopoiesis at the expense of monopoiesis in Alox15 mice. Restoration of
ROS rescues Alox15 monocyte differentiation. Thus, these data establish a novel
role for redox signaling in the regulation of nuclear accumulation and gene
transcription by IRF-8 and in monocyte differentiation in Alox15 mice. These
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findings have implications for leukemagenesis and inflammation.
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DISCUSSION
My dissertation defined novel roles for polyunsaturated fatty acid
metabolism mediated by 12/15-LOX during hematopoiesis. I found that 12/15LOX regulates the development of multiple hematopoietic cells including B cells,
T cells, basophils, RBC, and monocytes and the function of HSCs (Figure 52). I
demonstrate that disruption of 12/15-LOX signaling in Alox15 mice results in
macrocytic anemia, decreased numbers of lymphocytes, impaired HSC function
and skewed myeloid cell differentiation. The impaired HSC function and skewed
myeloid cell differentiation likely underlie the development of the granulocytic
MPN in a portion of Alox15 mice. Moreover, my data suggest that 12/15-LOX
may regulate HSC function at least in part through canonical Wnt signaling and
implicate redox signaling downstream of 12/15-LOX in the regulation of
ICSBP/IRF-8 transcriptional activity and monocyte development. These signaling
pathways have implications in the pathogenesis of immunity and cancer.
Moreover, my studies are the first to establish a role for polyunsaturated fatty
acid metabolism in vivo in the regulation of hematopoietic development and HSC
function.
Hematopoiesis
Although I have elucidated the mechanisms whereby 12/15-LOX regulates
monocyte development and HSC function, the mechanisms whereby 12/15-LOX
regulates B cell and T cell development remain of interest especially because
12/15-lipoxygenases have not been previously shown to regulate lymphoid
subsets. As we showed that 12/15-LOX regulates ICSBP/IRF-8 in multiple
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cell types, it is likely that 12/15-LOX also regulates B cell development through
ICSBP/IRF-8 as well. ICSBP/IRF-8 and a related transcription factor IRF-4
regulate B cell development at the preB cells stage and are required for
rearrangment of the IgG light chain (Lu et al., 2003) in part by mediating
transcription of Ikaros and Aiolos (Ma et al., 2008). Moreover, ICSBP/IRF-8deficient mice and Alox15 mice exhibit similar defects in B cell development (Lu
et al., 2003). Although the mechanism whereby 12/15-LOX regulates T cell
development is not known, lipoxygenase products are found in the thymus (Harizi
et al., 2008) and thus the defect in DP T cells in Alox15 mice may be due directly
to alterations in lipid mediators. In addition to lymphoid subsets, the role of 12/15LOX during DC differentiation could be potentially interesting, although we have
not yet explored this possibility. Because subsets of DC and monocytes share a
common progenitor (Geissmann et al., 2008) and because ICSBP/IRF-8 is also
known to regulate DC cell development (Aliberti et al., 2003; Tsujimura et al.,
2003), it is also possible that 12/15-LOX effects DC subsets.
Myelopoiesis
Because the oxidative enzymes involved in unsaturated fatty acid
metabolism compete for the same substrates, there may be cross-regulation
between cytochrome p450s, cyclooxygenases and lipoxygenases during
hematopoietic development due to substrate competition. In the absence of
12/15-LOX, there may be substrate re-diversion and enhanced activity of other
fatty acid enzymes. Indeed, we have shown that Alox15 BMM have increased
levels of 5(S)-HETE, a product of 5-LOX (Figure 45). 5-LOX has been shown
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to regulate granulocyte development through its product Leukotreine D4 (Miller et
al., 1990). Moreover, inhibition of 5-LOX potentiates monocyte development,
which is dependent upon p38MAPK activation (Stixova et al., 2009). On the other
hand, inhibition of COX-2 has yielded mixed results during myeloid development
(Hofmanova et al., 1998) (Bunce et al., 1994). Although, these studies were
conducted in cell lines, they demonstrate a seemingly opposing effect for 5-LOX
from what we have demonstrated for 12/15-LOX during monocyte development.
It is likely a balance of these enzymes and their products regulate myeloid
development (Figure 53).
The role of ROS signaling in myeloid development had not been
previously established. Although ROS levels were known to increase
macrophage development in part by NAPDH-oxidase (Barbieri et al., 2003), the
role of ROS signaling in immature myeloid differentiation was not previously
known. We demonstrated that ROS signaling generated by 12/15-LOX might
actually specify monocyte differentiation by promoting ICSBP/IRF-8 nuclear
accumulation. Moreover, we implicated SHP-2 as a redox sensitive factor
important in the regulation of ICSBP/IRF-8 and in the subsequent specification of
cell fate decisions. Although the role of ICSBP/IRF-8 in myeloid cell fate
decisions had been well documented (Tsujimura et al., 2002; Tamura et al.,
2000), its regulation by redox signaling was not previously known. Because
ICSBP/IRF-8 is present in multiple cell types other than myeloid progenitors
including B cells, dendritic cells, T cells and macrophages (Nelson et al., 1996;
Masumi et al., 2002; Tsujimura et al., 2003; Burchert et al., 2004) the
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regulation of ICSBP/IRF-8 by redox signaling may play a role in multiple cell
development and functions. Indeed, we showed that redox signaling might also
regulate transcriptional activation of IL-12p40 in macrophages.
There are multiple pathways in which ROS are generated including
NAPDH-oxidases, mitochondrial function and additional enzymes that participate
in fatty acid metabolism (Haddad, 2002a). Therefore, other oxidative enzymes or
cellular metabolism may participate in monocyte and granulocyte cell fate
decisions through redox-mediated modulation of ICSBP/IRF-8 nuclear
accumulation. However, it is possible that 12/15-LOX-mediated ROS production
occurs in a site-specific and concentration-dependent manner to specifically
regulate SHP-2 and ICSBP/IRF-8 during myelopoiesis and in mature
macrophages. Our data from HSCs in Data Chapter 2, support this hypothesis.
Although basal levels of ROS were increased in Alox15 LSK, 12/15-LOXdependent ROS were decreased. Moreover, Alox15 hematopoietic progenitors
exhibited decreased nuclear accumulation of ICSBP/IRF-8 and Alox15 LSK had
defective levels of ICSBP/IRF-8-mediated transcripts. Therefore, it is more likely
that 12/15-LOX-dependent ROS is a specific regulator of ICSBP/IRF-8
transcriptional activity, particularly in LSK. Nonetheless, it would be of interest to
determine the selectivity of ROS in the regulation of ICSBP/IRF-8 in various cell
types.
Although the role of SHP-2 in myeloid leukemia has been well
documented (Loh et al., 2004; Niihori et al., 2005; Schubbert et al., 2005), the
regulation of SHP-2 in myeloid cell fate decisions has only recently been
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demonstrated (Jack et al., 2009). Moreover, the role of SHP-2 in myeloid
differentiation is still under active investigation, as the contribution of SHP-1
versus SHP-2 is not known (Jack et al., 2009). Both SHP-1 and SHP-2 are
known to be negatively regulated by oxidative modification (Chen et al., 2009a;
Heneberg and Draber, 2005; Meng et al., 2002; Weibrecht et al., 2007) and both
can inhibit the transcriptional activity of ICSBP/IRF-8 through its dephosphorylation (Huang et al., 2006; Kautz et al., 2001). Since there was not a
selective inhibitor for SHP-1 or SHP-2, we used a phosphatase inhibitor, NSC87877, which inhibited both SHP-1 and SHP-2. Therefore, either SHP-1, SHP-2
or both may play a role in our signaling pathway by regulating ICSBP/IRF-8
through ROS signaling generated by 12/15-LOX. A future direction would be to
delineate the roles of SHP-1 and SHP-2 during monocyte and granulocyte cell
fate decisions in both wild-type and Alox15 mice.
HSC function
In addition to myelopoiesis, substrate competition for AA during fatty acid
metabolism may also regulate HSC function as summarized in Figure 54. COX-1
regulates formation of the hematopoietic niche while COX-2 directly regulates
HSC self-renewal and function (North et al., 2007). Furthermore, the COX
product PGE2 increases the number and function of LT-HSC (North et al., 2007)
by increasing homing, survival, proliferation and self-renewal (Hoggatt et al.,
2009). PGE2 functions by stimulating its receptor on HSC, activating PKA and
cAMP leading to stabilization of β-catenin by phosphorylation of GSK-3β and βcatenin (Goessling et al., 2009). Although the specific mechanisms whereby
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12/15-LOX and COX-2 regulate canonical Wnt signaling differ, 12/15-LOX
ultimately functions similarly to COX-2 by promoting β-catenin stabilization.
Interestingly, although 5-LOX does not play a major role in HSC function, it does
promote HSC differentiation to some extent (Chen et al., 2009b). Similar to its
role during myelopoieis, 5-LOX signaling may oppose 12/15-LOX signaling,
which we demonstrate functions to promote HSC self-renewal.
We demonstrated that basal levels of ROS are increased in Alox15 LSK.
The increased basal levels of ROS in Alox15 LSK could be a result of decreased
representation of LT-HSC, which express low levels of ROS compared to STHSC and MPP and are increased within Alox15 LSK (Jang and Sharkis, 2007).
However, the 12/15-LOX-independent ROS in HSC may be generated through
NAPDH-oxidases (Piccoli et al., 2007), mitochondrial function (Chen et al., 2008)
or other fatty acid oxidative enzymes such as 5-LOX (Chen et al., 2009b), which
have all been shown to contribute to HSC metabolism. It is possible that the
increased basal levels of ROS signal to negatively regulate HSC self-renewal
through activation of p38MAPK (Ito et al., 2006). The contribution of ROS by
12/15-LOX-dependent and independent mechanisms require further clarification.
Because ROS can be generated by multiple mechanisms, ROS levels differ in
various subcellular compartments, such as cell membrane versus mitochondrion,
which may play a role in its subsequent signaling. Modulation of ROS levels in a
subcellular compartment-dependent manner, will remain a challenge for future
studies.
Leukemia
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One result of altered hematopoiesis is leukemia. Disruptions in HSC
signaling can result in myeloid leukemogenesis (Passegue et al., 2004; Jamieson
et al., 2004; Yilmaz et al., 2006). Alternatively, a block in myeloid cell
differentiation can also cause myeloid leukemias (Holtschke et al., 1996;
Passegue et al., 2001; Mueller et al., 2002). However, these possibilities are not
mutually exclusive. Furthermore, we demonstrate that Alox15-deficient mice
exhibit disruptions in both HSC function and myeloid cell differentiation. It is likely
that both altered HSC function and a block in monocyte differentiation contribute
to the development of the CML-like leukemia in a proportion of Alox15 mice
(Middleton et al., 2006b).
We demonstrate that 12/15-LOX-generated ROS regulated ICSBP/IRF-8
nuclear accumulation possibly through SHP-2 inactivation. Interestingly,
regulation of ICSBP/IRF-8 by SHP-2 had been implicated in leukemia.
Constitutively active SHP-2 mutants synergized with haplo-insufficiency of
ICSBP/IRF-8 to mediate AML (Konieczna et al., 2008). Moreover, oncogenic
constitutively active SHP-2 mutants negatively regulated ICSBP/IRF-8
expression of NF-1 (Huang et al., 2006). Loss of NF-1 expression by inhibition of
ICSBP/IRF-8 contributed to leukemia progression (Koenigsmann et al., 2009).
Our data proposes a model in which inhibition of 12/15-LOX found in myeloid
leukemias (Stenke et al., 1991; Takayama et al., 1983) results in activation of
SHP-2 and defective ICSBP/IRF-8 transcriptional activity contributing to leukemia
progression.
Because 12/15-LOX regulated ICSBP/IRF-8 through redox regulation
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of SHP-2, one would hypothesize that either increasing ROS or inhibiting SHP-2
in Alox15 progenitors during leukemia could restore nuclear ICSBP to treat the
CML-like MPN in Alox15 mice. Since Alox15 cells lost transcriptional expression
of ICSBP during the leukemic phase of disease (Middleton et al., 2006b),
increasing ROS levels or inhibiting SHP-2 in Alox15 mice may be used to prevent
the development of leukemia rather than treat active leukemia. On the other
hand, increasing ROS levels or inhibiting SHP-2 in Alox15 mice may cause
activation of inflammatory gene transcription. Moreover, modulating ROS levels
are difficult since their effects are dose-, cell- and subcellular-context dependent.
In the setting of leukemic HSC, fatty acid metabolism mediated by 5-LOX
and 12/15-LOX may still have opposing functions (Figure 55). 5-LOX- deficient
HSC or treatment of wild-type HSC with a 5-LOX inhibitor protects against BcrAbl-induced CML (Chen et al., 2009b) demonstrating that 5-LOX positively
regulates leukemic HSC function. During human CML, expression and activity of
LTC4 synthase, an enzyme downstream of 5-LOX, was increased resulting in
higher levels of Leukotriene C4 (Tornhamre et al., 2003). LTC4 increased
proliferation of normal and leukemic hematopoietic progenitors in response to
GM-CSF (Snyder et al., 1989; Stenke et al., 1993). On the other hand, we
previously demonstrated that 12/15-LOX functions as a tumor suppressor and
protects against development of a CML-like disease (Middleton et al., 2006b).
Moreover, the common product of 5-LOX and 12/15-LOX Lipoxin A4 and a 12LOX product, 12(S)-HETE were decreased during human CML (Stenke et al.,
1991; Stenke et al., 1987). Furthermore, 12/15-LOX products promoted
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apoptosis of K562 leukemic cell line (Mahipal et al., 2007). Therefore, 5-LOX
promotes leukemogenesis and its products are increased during human CML,
12/15-LOX functions as a tumor suppressor and its products are decreased
during human CML. It is possible that substrate re-diversion in the absence of
12/15-LOX contributes to the CML-like MPN in Alox15 mice.
While 5-LOX and 12/15-LOX may oppose each other during
leukemogenesis, the role of COXs are less understood. While COX inhibitors did
not effect proliferation or apoptosis of leukemic cell lines (Snyder et al., 1989),
COX products Prostaglandin D2 and Prostaglandin J2 induced their cell death
(Chen et al., 2005). Thus, the role of COX-1 and COX-2 during leukemic
development requires further study.
Immunity
My data demonstrated that ROS signaling downstream of 12/15-LOX
mediated IL-12p40 gene expression in macrophages. Although it was previously
known that ROS signaling increases inflammatory gene transcription (Haddad,
2002b), we now demonstrate that signaling of ROS specifically generated by
12/15-LOX contributes to inflammatory cytokine gene expression. We identify
ICSBP/IRF-8 as a novel target downstream of redox signaling. As we previously
showed that NF-κB-mediated gene transcription of IL-12p40 was regulated by
12/15-LOX (Middleton et al., 2006a) and as it was known that NF-κB is regulated
by redox signaling (Haddad, 2002a), it is likely that ROS signaling mediated by
12/15-LOX also regulates NF-κB transcriptional activity.
Although we demonstrated that ROS signaling downstream of 12/15153

LOX regulated ICSBP/IRF-8 transcriptional activity, it is also likely that ROS
generated independently of 12/15-LOX regulates ICSBP/IRF-8 inflammatory
gene transcription. Inflammation and inflammatory cytokines can induce ROS
production through multiple mechanisms and in turn ROS-signaling contributes to
further inflammation and cytokine production (Haddad and Harb, 2005; Lambeth
et al., 2008; Shakibaei et al., 2005). Similarly, increased ROS levels during
inflammation may activate IRF-8 nuclear accumulation and transcriptional activity
of inflammatory cytokines in mature macrophages.
The role of 12/15-LOX has been extensively studied in the context of
chronic inflammation. For instance, it was known that 12/15-LOX contributed to
chronic inflammation and immunity in atherosclerosis and toxoplasma infection
(Cyrus et al., 2001; George et al., 2001; Zhao et al., 2002; Middleton, et al in
press). Moreover, it was known that 12/15-LOX regulated expression of
inflammatory cytokines in macrophages (Middleton et al., 2006a; Dioszeghy et
al., 2008). However, the signaling pathways whereby 12/15-LOX regulated
inflammatory gene transcription were not well understood. My studies
demonstrate a mechanism whereby 12/15-LOX may regulate inflammatory gene
transcription through redox signaling.
Cancer
In addition to leukemia, fatty acid metabolism mediated by 12/15-LOX may
also mediate solid tumor progression. Although my data demonstrate how 12/15LOX mediates signaling in hematopoietic cell types, it would be interesting to
determine whether 12/15-LOX promotes self-renewal during solid tumor
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progression similarly to how it regulates self-renewal of LSK. On the other hand,
since 12/15-LOX functions as a tumor suppressor in leukemia (Middleton et al.,
2006b), it is possible that 12/15-LOX functions as a tumor suppressor during
solid tumor progression. Our pathways demonstrate that 12/15-LOX may signal
through the immune cell specific transcription factor ICSBP/IRF-8 in
hematopoietic cells to mediate their effects. Nonetheless, since nonhematopoietic cells do not express ICSBP/IRF-8, it would be interesting to
determine whether there are effects of 12/15-LOX independent of ICSBP/IRF-8
on self-renewal, proliferation and cellular differentiation. Importantly, 12/15-LOX
may regulate canonical Wnt signaling and self-renewal independently of
ICSBP/IRF-8, possibly in a similar manner as the COX-2 and its product PGE2
(Goessling et al., 2009).
It was known that fatty acid metabolism of AA contributes to solid tumor
progression (Figure 56). While COX-1 is constitutively expressed in the majority
of both normal and neoplastic tissues, over-expression of COX-2 in both
epithelial and leukocyte compartments has been observed in many cancer types
including breast, esophageal, gastric, lung, prostate and pancreatic cancer
(Furstenberger et al., 2006). Moreover, use of non-steroidal anti-inflammatory
drugs (NSAIDs) such as aspirin, which function in part by targeting COX, can
reduce incidence and recurrence of several human cancers by up to 50% (Hyde
and Missailidis, 2009). More specific COX-2 inhibitors have been used in studies
to prevent colon cancer in high-risk populations. However, its long-term use is
limited because of increased risk of thrombotic events as described in the
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introduction of this dissertation. COX-2 functions to promote cancer by
stimulating inflammation, cancer cell proliferation, angiogenesis, cancer cell
survival and invasiveness. It signals in part through its lipid products, PGE2 and
PGF2 to activate RAS-MAPK and Wnt pathways (Furstenberger et al., 2006).
Interestingly, COX-2 activates Wnt signaling in multiple cancers similarly to how it
activates Wnt signaling in HSC, through inhibition of GSK3β resulting in
increased levels of β-catenin (Lim et al., 2008; Lu et al., 2009; Tuynman et al.,
2008). Wnt signaling promotes cell proliferation and self-renewal during cancer,
and its constitutive activation is oncogenic.
The role of lipoxygenases during cancer progression is more complicated.
The isoenzymes 5-LOX, platelet-12-LOX (p12-LOX) are pro-carcinogenic while
15-LOX-2 (mouse ortholog 8-LOX) is anti-carcinogenic. The role of 15-LOX-1
(mouse ortholog 12/15-LOX) is pro-carcinogenic in prostate cancer but anticarcinogenic during other cancer types. 5-LOX and p12-LOX are absent from
normal tissues, induced by inflammatory stimuli and over-expressed in colon,
esophageal, lung, prostate and breast cancer. Meanwhile, 15-LOX-1 and 15LOX-2 are generally expressed only in benign tissues and not in carcincomas. In
some cancers decreased expression of 15-LOX coupled with increased
expression of p12-LOX is a prognostic of poor tumor outcome. 5-LOX and p12LOX increase cancer cell proliferation, survival and invasiveness. Both 5-LOX
and p12-LOX promote angiogenesis by stimulating endothelial cell proliferation
and inducing VEGF expression. Inhibition of 5-LOX or p12-LOX results in
apoptosis of breast cancer, colon, gastric, lung and prostate cancers
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(Pidgeon et al., 2007). Moreover, inhibition of multiple LOX and COX in
combination (such has inhibition of 5-LOX and COX-2) may be beneficial since
substrate re-diversion occurs resulting in increased activation of one pathway
when the other is inhibited (Schroeder et al., 2007). On the other hand 15-LOX-2
functions as a tumor suppressor in multiple cancer types by promoting cell
differentiation and senescence (Pidgeon et al., 2007; Tang et al., 2007).
Although 15-LOX-1 is anti-carcinogenic for most cancer types, its role in
prostate cancer is pro-carcinogenic. 15-LOX-1 expression is correlated to tumor
grade in human prostate cancers (Pidgeon et al., 2007) and expression of its
murine ortholog 12/15-LOX is induced in multiple mouse models of prostate
cancer (Shappell et al., 2003; Kelavkar et al., 2004). In addition, induced
expression of 15-LOX-1 in the prostate results in epithelial proliferation and
prostatic intraepithelial neoplasia (Kelavkar et al., 2006). The apparent
discrepancy in the role of 15-LOX-1 in distinct tumor types can be resolved by
comparing the products involved. The lipid mediators 12(S)-HETE and 13(S)HODE are pro-carcinogenic while 15(S)-HETE is generally anti-carcinogenic
(Figure 56). 12(S)-HETE activated NF-κB, Erk and p38MAPK to stimulate cell
growth, angiogenesis and invasiveness. 13(S)-HODE increased MAPK and Akt
activation while 15(S)-HETE decreased activation of MAPK and Akt (Pidgeon et
al., 2007). Human p12-LOX generates 12(S)-HETE exclusively while 15-LOX-1
generates both 13(S)-HODE and 15(S)-HETE and 15-LOX-2 generates 15(S)HETE exclusively. 15-LOX-1 may produce different levels of 13(S)-HODE and
15(S)-HETE in different cell types in the prostate. Nonetheless murine 12/15158

LOX produces 12(S)-HETE and 15(S)-HETE at a ratio of 3:1 (Chen et al., 1994)
in addition to generating 13(S)-HODE. It is likely that murine 12/15-LOX functions
more similarly to human p12LOX because of the higher levels of procarcinogenic 12(S)-HETE produced rather than its human ortholog 15-LOX-1
which does not produce a substantial amount of 12(S)-HETE.
The study of 12/15-LOX products during tumor progression stresses the
importance of understanding the balance of products and downstream signaling
pathways. Substrate re-diversion may also play a role during Alox15
carcinogenesis. It would be interesting to explore whether increased COX and 5LOX activity could contribute to carcinogenesis in Alox15 mice.
Since human p12-LOX and 12/15-LOX are pro-carcinogenic, it would be
of interest to determine whether they promote cancer proliferation through Wnt
activation similarly to COX-2. Specifically, because the pro-carcinogenic lipid
mediators 12(S)-HETE and 13(S)-HODE were decreased in Alox15 HSC which
had defective canonical Wnt signaling, 12(S)-HETE and 13(S)-HODE may
regulate Wnt signaling and self-renewal to promote cancer progression. The
effect of 12/15-LOX as a tumor suppressor in leukemia may be dependent on
ICSBP/IRF-8 since it does not function as a tumor suppressor in solid tumors.
Although 15(S)-HETE is anti-carcinogenic in solid tumors, it is unlikely to be anticarcinogenic during leukemia since its levels are not changed during human CML
and Alox15 CML-like MPN (Middleton et al., 2006b) (Stenke et al., 1987).
Summary
In summary, my dissertation demonstrates critical roles for 12/15-LOX
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in hematopoietic development of multiple cell types. These are the first studies
that effectively demonstrate a role for fatty acid metabolism in hematopoietic
development in vivo. I have defined novel signaling pathways in HSC function
and myeloid development. 12/15-LOX promotes self-renewal and maintains
quiescence of HSC through canonical Wnt signaling. Moreover, 12/15-LOX
mediates monocyte differentiation and inhibits granulocyte differentiation through
redox regulation of ICSBP/IRF-8 transcriptional activity through SHP-2. I have
shown that this signaling pathway is also likely intact during macrophage
regulation of IL-12p40, which has implications for inflammation and immunity.
Moreover, these data provide insight into HSC function and myelopoiesis. The
signaling pathways that I have elucidated likely underlie development of the
CML-like MPN in Alox15 mice and therefore have implications for
leukemogenesis and tumorigenesis.
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